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ABSTRACT
ROLE OF 5-HT1A RECEPTORS IN THE ABILITY OF IDAZOXAN AND
RACLOPRIDE TO BLOCK CONDITIONED AVOIDANCE RESPONDING
By
Sarah M. Jacobson
Atypical antipsychotic drugs (APD)s are regarded as more effective and safer
than typical APDs for the treatment of schizophrenia. The hypothesis that combined
blockade of α2 and D2 receptors produces atypical APD effects has been supported by
the ability of the α2 receptor antagonist idazoxan (IDX) combined with a low dose of
the D2 receptor antagonist raclopride (RAC) to block conditioned avoidance
responding in rats. However, IDX is also a partial agonist at 5-HT1A receptors. The
present study sought to clarify the role of 5-HT1A receptors in the effects of IDX
combined with RAC, on conditioned avoidance responding in 16 male Sprague
Dawley rats using a two-chamber shuttlebox equipped with a tilting grid floor. The
α2 adrenoceptor antagonist, yohimbine (YOH), was also tested in combination with
RAC. RAC dose-dependently inhibited avoidance responding. IDX and YOH
decreased avoidance responding when paired with an ineffective dose of RAC.
Pretreatment with the 5-HT1A receptor antagonist WAY100635 failed to significantly
alter the avoidance rate of the IDX and RAC combination. The α2 adrenoceptor
agonist, guanfacine, restored deficits in responding induced by the RAC+IDX
treatment. The 5-HT1A agonist 8-OH-DPAT reduced avoidance responding when
paired with the ineffective dose of RAC. Based on these findings, α2 receptor
blockade, not 5-HT1A receptor stimulation, appears to mediate the ability of IDX and
RAC to block conditioned avoidance responding.
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INTRODUCTION
Schizophrenia is a debilitating, lifelong mental illness diagnosed in
approximately 1 percent of the worldwide population (Freedman, 2003), and is
characterized by positive (e.g. hallucinations, delusions) and negative (e.g. alogia,
anhedonia) symptoms and cognitive impairments (working memory and attention).
Schizophrenia has been described as the world’s most expensive mental illness, due
to the progressive deterioration of patients over the course of a lifetime, which
subsequently places a lasting financial burden on society. Much of the cost of the
treatment of schizophrenia is due to poor adherence to pharmacological treatment
programs, which in turn leads to hospitalization. It is estimated that repeated
hospitalizations cost approximately $806 million annually (Marcus & Olfson, 2008).
Many patients do not experience a significant recovery from symptoms, even with
modern pharmacotherapeutic therapies.
The Diagnostic and Statistical Manual of Mental Disorders (DSM) lists
comprehensive diagnostic criteria for the diagnosis of schizophrenia and defines
specific subtypes of schizophrenia. The DSM specifies that patients must exhibit two
or more of the following symptoms for a significant portion of a one-month period:
delusions, hallucinations, disorganized speech, grossly disorganized or catatonic
behavior, or negative symptoms. Delusions or hallucinations alone, however, are
sufficient to diagnose schizophrenia if the clinician notes that they are especially
bizarre or disruptive of normal behavior. Patients who are diagnosed with
schizophrenia per DSM criteria must also experience a significant decrease in social
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functioning, including maintaining employment and personal relationships.
Symptoms must be persistent for the duration of 6 months prior to treatment
intervention without the occurrence of a major depressive or manic behavioral
episode. Symptoms must not be directly related to the effects of substance abuse
(American Psychiatric Association [DSM-IV-TR], 2000).
History of Treatment
Prior to the discovery of pharmacological treatments for schizophrenia,
patients were commonly sedated, restrained or subject to electroconvulsive therapy,
ice-baths or frontal lobotomies. These treatments offered very limited gains in
improving the symptoms of schizophrenia. Psychiatric treatment was transformed by
the introduction of chlorpromazine in 1952. This treatment represented the first
typical antipsychotic and significantly reduced psychotic symptoms in 70% of
patients (Meyer & Simpson, 1997).
Chlorpromazine and similar drugs developed later, now referred to as typical,
or first generation antipsychotic drugs, only proved effective in reducing positive
symptoms, and did not improve negative symptoms and cognitive impairments.
Additionally, patients treated with typical antipsychotic drugs frequently developed
movement disorders, referred to as extrapyramidal symptoms (EPS), which could be
relieved by discontinuation of drug treatment. In some cases a class of movement
disorders, called tardive dyskinesia, developed following chronic typical
antipsychotic drug administration, which persisted after discontinuation of treatment
(Meltzer & Stahl, 1976; Meyer & Simpson, 1997). Despite such setbacks, the
discovery of a pharmacologically effective treatment for schizophrenia provided an
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important foundation from which to base hypotheses regarding the causes of
schizophrenia, the first being the dopamine hypothesis of schizophrenia.
Dopamine Hypothesis
A comprehensive review by Meltzer and Stahl (1976) describes the dopamine
hypothesis of schizophrenia based on evidence from three categories: the ability of
antipsychotic drugs to reduce positive symptoms, the phenomenon of amphetamine
psychosis (which resembles the psychotic symptoms of schizophrenia) and
pharmacological studies carried out in animal models of psychosis. These lines of
evidence show that increases in dopamine activity are correlated with psychotic
symptoms and that drugs that block the activity of dopamine alleviate psychotic
symptoms in patients with schizophrenia.
Amphetamine Psychosis
Randrup and Munkvad (1967) demonstrated that a drug that stimulates
dopamine receptors, amphetamine, induces behaviors termed stereotypy in rats, mice,
guinea pigs and monkeys. Amphetamine-induced stereotypy is defined as a behavior
that is performed continuously or purposelessly, such as continuous grooming of a
single limb or purposeless searching head movements. Stereotypy interrupts normal
grooming and exploring behaviors. In the absence of stereotypy, amphetamine
increases the frequency of normal behaviors from that of baseline. Decreases in
purposeful behaviors through a replacement by non-productive behaviors are
associated with the agitated and disorganized behavior of patients with schizophrenia.
Because stereotypy was produced through agonism of dopamine receptors, it was
then hypothesized that psychotic symptoms are resultant from increases in dopamine
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activity in the brain (e.g. see Carlsson & Lindqvist, 1963; Meltzer & Stahl, 1976 for
review). Further animal studies in cats supported the dopamine hypothesis by
showing that long- and short-term amphetamine treatment produced significant
changes in brain chemistry, including a 95% increase in dopamine levels in the
striatum (Trulson & Jacobs, 1979).
Studies in humans using amphetamine and other dopamine agonists also
support the dopamine hypothesis of schizophrenia. Clinical measures of psychotic
behavior are significantly increased by the administration of the synthetic dopamine
precursor L-Dopa in patients with schizophrenia (Yaryura-Tobias, Diamond, &
Merlis, 1970). Furthermore, L-Dopa treatment in patients with Parkinson’s Disease
increases dopamine levels in the nigrostriatal region and has the potential to induce
psychotic symptoms over time (Meltzer & Stahl, 1976). Positron emission
tomography research shows that patients with schizophrenia have greater dopamine
release in response to amphetamine administration, termed amphetamine challenge,
compared to healthy controls (Breier et al., 1997). Such increases in dopamine
release in response to amphetamine administration are correlated with a significant
worsening of positive symptamology, which is greater in patients with schizophrenia
than in healthy control subjects (Laurelle et al., 1996).
Antipsychotic drugs
Typical antipsychotic drugs are used to support the hypothesis of dopamine
overactivity in schizophrenia. Seeman (1975) showed a strong positive correlation
between the strength of dopamine D2 receptor blockade, a characteristic shared by
nearly all typical antipsychotic drugs, and clinically effective dose of an
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antipsychotic. These clinically prescribed doses are also effective in reversing
amphetamine-induced psychosis in healthy controls. Specifically, the typical
antipsychotic haloperidol significantly attenuates amphetamine-induced increases in
psychotic behavior. In addition to alleviating psychosis in healthy controls,
haloperidol significantly improves psychotic symptoms in amphetamine addicts as
well as in schizophrenic patients and is effective in treating psychosis induced by
long-term L-DOPA treatment in patients with Parkinson’s disease (Angrist, Lee &
Gershon, 1974).
Angrist and colleagues (1980) studied amphetamine treatment in unmedicated
patients with schizophrenia to further explore the relationship between antipsychotic
treatment response and sensitivity to amphetamine. Their research found that patients
with a higher sensitivity to amphetamine also had a greater improvement in psychotic
symptoms with antipsychotic treatment. Additionally, treatment-resistant patients
showed less sensitivity to amphetamine. These findings indicated a need to explore
dysfunction in neurotransmission beyond that of dopamine hyperfunction, especially
in patients that are insensitive to typical antipsychotic drug treatment.
Negative symptoms and cognitive impairments
While chlorpromazine initiated a dramatic change in the treatment of patients
with schizophrenia, the drugs synthesized after its discovery increased in potency but
not in efficacy (Freedman, 2003). A population of patients still remained who were
not effectively treated by dopamine D2 receptor antagonists. Discoveries made by
Angrist and colleagues (1980) regarding the relationship between amphetamine
sensitivity and antipsychotic response were supported by further research showing
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that patients insensitive to apomorphine treatment were also treatment-resistant when
administered typical antipsychotic drugs (Garver, Zelman, Hirschowitz, Hitzemann,
& Mavroidis, 1984). Evidence has been found indicating that dopamine
hyperfunction in the mesolimbic system is also present in patients who have
dopamine hypofunction in mesocortical regions (see Svensson, 2003 for review). In
such cases, a pure dopamine receptor antagonist would be ineffective in treating all
symptoms affecting patients with schizophrenia.
Persistent blockade of dopamine receptors can cause Parkinson-like
movement disorders, often referred to as extrapyramidal side effects (EPS).
Dopamine deficiencies caused by dopamine antagonism interrupt the functioning of
the nigrostriatal (mesostriatal) dopamine tract, which regulates the extrapyramidal
nervous system (Hornykiewicz, 1966; Klawans, 1973; Randrup & Munkvad, 1970).
It follows that dopamine antagonists, typical antipsychotic drugs, are implicated in
deterioration of normal motor control.
Adverse effects associated with typical antipsychotic drug treatment are not
limited to movement disorders, and include decreases in cognitive functioning, which
is often already abnormal in schizophrenia (Mehta, Montgomery, Kitamura, &
Grasby, 2008). Depleting dopamine in the prefrontal cortex has cognitive effects
similar to that of ablation of prefrontal cortical areas in rhesus monkeys. Reversal of
cognitive deficits induced by dopamine depletion can be achieved by administration
of the synthetic dopamine precursor L-DOPA, or the dopamine receptor agonist
apomorphine, suggesting that dopamine activity is important for normal cognitive
functioning (Brozoski, Brown, Rosvold, & Goldman, 1979). Therefore, antipsychotic
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drugs that antagonize the effects of dopamine in areas important for cognition may
worsen cognitive deficits in patients with schizophrenia.
Cognitive impairments are most strongly related to functional outcome in
patients with schizophrenia. Measures of functional outcome include the ability to
maintain meaningful personal relationships, carry out daily living routines and
successfully retain a job. Impairments in cognitive functions, such as episodic
memory, working memory and sustained attention are persistent across most
published clinical studies of patients with schizophrenia (see Sharma & Antonova,
2003 for review). The presence of severe cognitive dysfunction negatively impacts
patient functional outcomes. Milev and colleagues (2005) further supported these
data by finding that impairments of verbal memory, processing speed and attention
are negatively related to functional outcome, specifically, work performance. The
typical antipsychotic, haloperidol, was found by Saeedi and colleagues (2006) to
dose-dependently produce deficits in sustained attention and reaction time in healthy
volunteers. Attention and working memory are impaired in healthy volunteers given
the typical antipsychotic sulpiride at doses below what would be considered clinically
effective (Mehta et al., 2008). Furthermore, high dopamine D2 receptor occupancy is
correlated with depression and decreases in self-control and emotional regulation (de
Haan, Lavalaye, Linszen, Dingemans, & Booij, 2000).
For some time, researchers questioned whether or not dopamine receptor
antagonism was an essential feature of antipsychotic action. Greenblatt and
colleagues (1980) argued that dopamine antagonism is not necessary for antipsychotic
effects. Their research found that the 5-HT2A/2C agonist, cis-5,6-Dimethoxy-2-
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methyl-3-[2-(4-phenyl-1-piperazinyl)-ethyl]indoline (DHO), was more effective in
inhibiting locomotor activity than chlorpromazine. DHO was not, however, as
effective in protecting against lethal doses of amphetamine as chlorpromazine, and
DHO caused increases rather than decreases in amphetamine-induced stereotypy.
Thus, DHO is not a dopamine antagonist, but has characteristics that could be
considered desirable in a typical antipsychotic drug.
Atypical antipsychotic drugs
The class of drugs developed to address the shortcomings of typical
antipsychotic drugs are known as atypical antipsychotics, the first of which,
clozapine, was approved for use in the United States in 1989 (Jibson & Tandon,
1998). Clozapine is the first known antipsychotic effective for both positive and
negative symptoms and to also have a low EPS liability. Treatment with clozapine,
however, occasionally results in seizures and dangerous declines in white blood cell
counts, known as agranulocytosis (Meyer & Simpson, 1997). Despite these
drawbacks, clozapine is still sometimes used in treatment-resistant patients in
conjunction with frequent blood draws to monitor white blood cell counts (Kane,
Honigfeld, Singer, & Meltzer, 1988). Patients treated with clozapine have
improvements in memory, attention and executive function as well as improvements
in positive symptamology (Hagger et al., 1993). Symptom improvements with
clozapine are correlated with discharge from inpatient psychiatric facilities
(Manschreck, Redmond, Candela, & Maher, 1999) and decreases in suicidal behavior
(Meltzer et al., 2003).
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The receptor binding profile of clozapine has been used in clarifying the
characteristics found in effective antipsychotic drug treatment. Compared to typical
antipsychotic drugs, clozapine has a much lower affinity for dopamine D 2 receptors.
Furthermore, clozapine has actions at serotonin (5-HT) receptors as well as
adrenoceptors in the brain. At the 5-HT1A receptor subtype, clozapine acts as an
agonist. Alternatively, clozapine acts as an antagonist at 5-HT2A receptors and at α2
adrenoceptors (for review, see Ashby & Wang, 1996).
Positive outcomes following clozapine treatment prompted the development
of other antipsychotics with a receptor binding profile similar to that of clozapine but
without the dangerous side effects. In 1994, risperidone was approved for use in the
United States (Jibson & Tandon, 1998). Risperidone was the first atypical
antipsychotic drug developed after clozapine, and had efficacy for both positive and
negative symptoms. Patients treated with higher doses of risperidone, however, often
develop extrapyramidal side effects. Similar to clozapine and risperidone, olanzapine
has a diverse receptor binding profile, is effective for both positive and negative
symptoms of schizophrenia and has low EPS liability. Olanzapine is effective at low
doses, more effective than typical antipsychotics in reducing the positive and negative
symptoms of schizophrenia and less likely to induce movement disorders compared
to typical antipsychotics (Meyer & Simpson, 1997).
Theories of antipsychotic atypicality
D2/5-HT2A hypothesis
Animal models using amphetamine to induce psychotic stereotypy produce
abnormalities not only in dopamine but also in serotonin. Short-term amphetamine

9

treatment greatly increases dopamine levels in the striatum, which may be responsible
for producing psychotic stereotypy. Long-term amphetamine administration
decreases serotonin and its metabolites in the hippocampus, striatum and
diencephalon (Trulson & Jacobs, 1979). Treatment with LSD, a 5-HT agonist,
produces hallucinations, a positive symptom of schizophrenia, which has been linked
to 5-HT2A stimulation (Fiorella, Rabin, & Winter, 1995).
Serotonin receptors are abnormal in patients with schizophrenia. Frontal
cortical serotonin receptors are decreased in patients with schizophrenia as compared
to age- and gender-matched controls and normal patients have age-related serotonin
receptor decreases while patients with schizophrenia of all ages have decreases in
serotonin receptors, specifically the 2A subtype (Dean & Hayes, 1996). These data
are indicative of either a failure to synthesize 5-HT2A receptors, or uninhibited
pruning of the receptors in early life. In either case, this abnormality may be an
important factor underlying the symptoms of schizophrenia. It is important to note,
however, that the certain polymorphisms of the genes responsible for 5-HT2A receptor
expression in patients with schizophrenia have not been found to be significantly
different from normal control subjects (Bertola, Cordeiro, Zung, Miracca, & Vallada,
2007).
Meltzer (1989) proposed the D2/5-HT2A hypothesis of antipsychotic
atypicality based upon the observation that antipsychotic drugs with a higher affinity
for 5-HT2A receptors over D2 receptors have higher clinical efficacy for treating
positive and negative symptoms and have lower EPS liability. Studies using positron
emission tomography in humans have found that patients treated with atypical versus
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typical antipsychotic drugs have higher 5-HT2A binding relative to D2 binding. These
observations include the prototypical atypical antipsychotic, clozapine (Goyer et al.,
1996; Nordstrom, Farde, & Halldin, 1993). Currently, all known atypical
antipsychotic drugs have a higher affinity for the 5-HT2A receptor over the D2
receptor (Jibson & Tandon, 1998; Meltzer, Li, Huang, & Prus, 2006), with the
exception of amisulpride, which stimulates dopamine D2/3 receptors and has no
affinity for 5-HT receptors (Natesan, Reckless, Barlow, Nobrega, & Kapur, 2008) and
aripiprazole, which has a greater affinity for D 2/3 receptors over 5-HT2A receptors
(DeLeon, Patel, & Crismon, 2004).
Seeman (2002) opposed this theory of antipsychotic atypicality in favor of the
dopamine D2 “fast-off” theory. Seeman noted that older antipsychotic drugs, such as
chlorpromazine and haloperidol bind tightly to dopamine D 2 receptors and are not
easily displaced by endogenous dopamine. Newer, atypical antipsychotics, however,
are more easily dissociated from dopamine D2 receptors, allowing endogenous
dopamine to bind to and activate the receptor, thus reducing EPS liability.
5-HT2A receptor involvement
While blockade of 5-HT2A receptors alone does not have an antipsychotic
effect, the addition of a 5-HT2A antagonist to a typical antipsychotic drug treatment
potentiates the effects of a typical antipsychotic in pre-clinical studies. This
combination does not worsen measures of catalepsy which predict EPS in humans
(Ellenbroek, Prinssen, & Cools, 1994; Wadenberg et al., 2000; Wadenberg, Hicks,
Richter, & Young, 1998; Wadenberg, Salmi, Jimenez, Svensson, & Ahlenius, 1996).
Therefore, administration of a 5-HT2A antagonist in combination with a typical
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antipsychotic produces a drug profile which resembles the effects of known atypical
antipsychotic drugs. Efficacy may be improved without increasing the amount of
dopamine antagonism, which in turn reduces the likelihood of inducing EPS.
Blockade of 5-HT2A receptors in mice reduces amphetamine-induced motor activity,
further suggesting the protective effects of 5-HT2A antagonism on motor systems in
the brain (Moser, Moran, Frank, & Kehne, 1996). Reversing the 5-HT2A antagonistic
effects of atypical antipsychotics provides further evidence for the 5-HT2A/D2
hypothesis of atypicality. Stimulation of 5-HT2A receptors in combination with
clozapine treatment reduces measures in animal models that predict clinical efficacy,
suggesting that 5-HT2A antagonism accounts, at least in part, for the effects of
clozapine (Ellenbroek et al., 1994).
Microdialysis studies by Marcus and colleagues (2000) show that 5-HT2A
antagonism potentiates dopamine release preferentially in non-motor associated
regions, such as the prefrontal cortex, contributing to increased treatment efficacy and
decreased EPS liability. Increases of dopamine in prefrontal cortical areas do not,
however, occur with 5-HT2A antagonism alone. When paired with a dopamine
antagonist such as haloperidol, 5-HT2A antagonism increases dopamine in the
prefrontal cortex, while dopamine increases in motor regions induced by haloperidol
are significantly attenuated (Liegeois, Ichikawa, & Meltzer, 2002).
5-HT 1A receptor involvement
Serotonin 1A receptor agonism has been suggested to contribute to an atypical
antipsychotic drug profile. Specifically, 5-HT1A agonism may reduce the occurrence
of EPS induced by dopamine antagonism. Conversely, antagonism of 5-HT1A
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receptors increases the EPS liability of typical antipsychotic drugs. Depletion of
serotonin, however, eliminates this enhancement of cataleptic effects (Prinssen,
Colpaert, & Koek, 2002; Prinssen, Koek, & Kleven, 2000).
Research investigating neurochemicals in specific brain regions has supported
the potential role of 5-HT1A agonism in atypical antipsychotic drug effects. Serotonin
1A agonism has been shown by Ichikawa and colleagues (1995) to attenuate the
effects of amphetamine on the release of dopamine in the striatum and the nucleus
accumbens. Stimulation of 5-HT1A receptors in combination with typical
antipsychotic drug treatment decreases dopamine levels in these areas, presumably
imparting a decreased EPS liability to the typical antipsychotic drugs tested (Ichikawa
& Meltzer, 2002). Behavioral studies by Ellenbroek and colleagues (1994) support
the neurochemical evidence by showing that administration of a 5-HT1A agonist
reduces typical antipsychotic-induced movement disorders while preserving drug
efficacy. Alternatively, blocking 5-HT1A receptors decreases the efficacy in treating
positive and negative symptoms of atypical antipsychotic drugs such as clozapine.
Clozapine-induced increases in prefrontal cortical dopamine release are inhibited by
co-treatment with a 5-HT1A antagonist (Rollema, Lu, Schmidt, & Zorn, 1997) while
behavioral measures of the clinical efficacy of clozapine are enhanced by cotreatment with a 5-HT1A agonist (Ellenbroek et al., 1994).
Adrenoceptors
α1 adrenoceptor receptor involvement
The atypical antipsychotic drugs clozapine and risperidone both have an
affinity for the α1 adrenoceptor, and blockade of this receptor has been implicated in
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mediating the activity of the mesolimbic dopamine system (Mathe, Nomikos,
Hildebrand, Hertel, & Svensson, 1996; Svensson, 2003). Marcus and colleagues
(2000) suggested that antagonism of α1 receptors inhibits typical antipsychoticinduced dopamine increases in motor regions of the nucleus accumbens, thereby
decreasing EPS liability.
Sensory-motor gating deficits, which are known to be impaired in
schizophrenic patients, can be blocked in animal models by the α1 antagonist prazosin
(Bakshi & Geyer, 1997). Agonism of these receptors disrupts normal sensory-motor
gating in animal models, providing further evidence that this receptor mechanism
contributes to the efficacy of atypical antipsychotic drugs such as clozapine (Carasso,
Bakshi, & Geyer, 1998). Alpha1 adrenoceptor blockade does not, however, protect
against EPS induced by typical antipsychotic drug treatment (Wadenberg & Hertel et
al., 2000).
α2 adrenoceptor receptor involvement
Increased affinity for α2 adrenoceptor antagonism over 5-HT2A/D2 receptor
antagonism has been suggested to contribute to an efficacious antipsychotic drug
profile. The atypical antipsychotic olanzapine, which is 40 times more potent at α 2
adrenoceptors than clozapine, but has a similar 5-HT2A/D2 binding profile, is effective
at much lower doses than clozapine (Meyer & Simpson, 1997). The protective
effects of α2 adrenoceptor antagonists on typical and atypical antipsychotic druginduced EPS has been demonstrated by a number of researchers. Invernizzi and
colleagues (2003) reversed the cataleptic effects of the typical antipsychotic drug,
haloperidol, through α2 adrenoceptor receptor blockade. Catalepsy induced by high
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doses of atypical antipsychotic drugs, whose action is mediated through D2/5-HT2A
antagonism, can also be reduced by α2 antagonism (Kalkman, Neurmann, Hoyer, &
Tricklebank, 1998). Increases in 5-HT in response to α2 antagonism have been noted
in in vivo neurochemical studies, which, given the evidence regarding the protective
effects of 5-HT1A agonism on dopamine-antagonist induced EPS, further supports the
hypothesis that α2 antagonism plays a role in antipsychotic atypicality (Hertel,
Nomikos, Schilstrom, Arborelius, & Svensson, 1997).
α2/D2 hypothesis
Hertel, Nomikos, & Svensson (1999) first proposed the α2/D2 hypothesis of
antipsychotic atypicality based upon behavioral tests as well as in vivo microdialysis
in rats. They found that the effects of a typical antipsychotic drug, which blocks
dopamine D2 receptors, is enhanced by co-treatment with an α2 adrenergic receptor
antagonist. The research showed that dopamine levels in the prefrontal cortex are
significantly higher in rats treated with an α2/D2 receptor antagonist combination
compared to rats treated with either drug alone. Furthermore, behavioral tests showed
this combination has greater antipsychotic efficacy than either drug given alone. The
effects of the α2/D2 receptor blockade were compared to that of clozapine and even
proposed to be more effective than clozapine in the treatment of schizophrenia.
Nearly all of the evidence used in support of the α2/D2 hypothesis of
antipsychotic atypicality has been through the use of a drug called idazoxan. The
distribution of idazoxan in the rat brain is consistent with that of known α2
adrenoceptor distribution (Mallard, Hudson, & Nutt, 1992). Idazoxan has therefore
been used in a variety of animal models exploring how antagonism of α2 receptors
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contributes to an atypical antipsychotic drug profile. It is important to note, however,
that 5-HT1A receptor stimulation has been implicated in the ability of idazoxan to
produce an atypical antipsychotic profile when paired with a typical antipsychotic
drug. Specifically, 5-HT1A stimulation is thought be responsible for the ability of
idazoxan to reduce the EPS liability of a typical antipsychotic drug (Kleven, Assie,
Cosi, Barret-Grevoz, & Newman-Tancredi, 2005).
Combining idazoxan with a typical antipsychotic drug reverses drug-induced
memory impairments in rats. These impairments can also be reversed by clozapine
treatment alone, and the treatments share a similar level of receptor binding at the
dopamine D2 receptor and α2 adrenoceptors (Marcus et al., 2005). Catalepsy induced
by typical antipsychotic drugs can be reversed using idazoxan, and idazoxan alone,
even at very high doses, does not induce catalepsy in rats (Wadenberg, Wiker, &
Svensson, 2007). Anti-cataleptic effects are further shown in studies that indicate
idazoxan treatment, both alone and in conjunction with typical antipsychotic drug
treatment, prevents dopamine increases in areas that are implicated in the
development of EPS (Invernizzi, Garavaglia, & Samanin, 2003). Furthermore,
idazoxan treatment in conjunction with dopamine antagonism increases dopamine in
the prefrontal cortex, implying that this treatment would be effective in reducing
cognitive symptoms associated with schizophrenia (Hertel, Nomikos, & Svensson,
1999). By blocking α2 adrenoceptors, clozapine-induced dopamine and
norepinepherine increases in the prefrontal cortex are inhibited, suggesting that the α2
antagonistic properties of clozapine contribute to its favorable clinical effects (Devoto
et al., 2003). Smith, Wilson, Glue, & Nutt (1992) supported this hypothesis by
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showing that idazoxan treatments in healthy human subjects did not affect memory,
attention, or mood.

17

Table 1. Receptor binding affinities for typical and atypical antipsychotic drugs at
dopamine, serotonin and adrenergic receptors in the brain. Binding results (Ki) for
haloperidol, clozapine, risperidone and olanzapine were reported by Schotte et al.
(1996). Alpha2 binding results (Ki) for olanzapine were reported by Bymaster et al.
(1996). D2 and 5-HT2A results (Kd) for raclopride were reported by Seeman et al.
(1997). Binding results for idazoxan, yohimbine, 8-OH-DPAT and chlorpromazine
at D2, 5-HT1A and 5-HT2A (Ki) were reported by Toll et al. (1998), α1 and α2 binding
results (Ki) for idazoxan and yohimbine were reported by Doxey et al. (1984).
Binding results (Kd) for WAY100635 were reported by Chemel et al. (2006). α 1 and
α2 results (Ki) for chlorpromazine and raclopride were reported by Hall et al. (1986)
as well as 5-HT1A results for raclopride. Binding results (Ki) for Guanfacine were
reported by Boyajian et al. (1987).
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Table 1. Receptor binding affinities for selected typical and atypical antipsychotic
drugs
Antipsychotic

D2

α1

α2

5-HT1A

5-HT2A

Chlorpromazine 3.0

14

3,050

3,115

3.6

Haloperidol

1.4

19

>5,000

3,080

25

Clozapine

150

23

160

180

3.3

Risperidone

3.3

2.3

7.5

250

0.16

Olanzapine

17

60

230

2,720

1.9

Raclopride

0.64

32,300

38,200

48,800

5,400

Idazoxan

>10,000

91

3.1

662

>10,000

Yohimbine

280

230

40

642

2,258

WAY100635

940

19.9

>10,000

2.2

6,2600

8-OH-DPAT

1,788

-

-

6.9

>10,000

Guanfacine

-

-

24.9

-

-
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Models for studying potential antipsychotic drugs
Catalepsy test
The catalepsy test is the most frequently used test for the study of EPS. The
test is performed by injecting an animal with the drug/s of interest, waiting a set
period for onset of drug action and then placing the animal in an unusual position.
The catalepsy score is based upon the amount of time the animal takes to correct its
position (Sandberg, Bunsey, Giordano, & Norman, 1988). Catalepsy was considered
at one time to be a desirable effect in potential antipsychotic drug treatments, but is
now considered to be detrimental.
Measuring the effects of specific receptor agonists and antagonists on typical
antipsychotic-induced catalepsy is a useful tool for developing atypical antipsychotic
drugs with low EPS liability. Drugs that are known to induce catalepsy are paired
with experimental therapeutics specific for a particular receptor in the brain to clarify
the mechanisms involved in reducing EPS and developing atypical antipsychotic
drugs. The catalepsy test is not, however, effective in discriminating between typical
and atypical antipsychotic drugs. Researchers have also noted that typical
antipsychotic-induced catalepsy appears to be similar to narcotic-induced catatonia.
Therefore, the catalepsy test may not always be effective in determining whether or
not a drug is an antipsychotic. To differentiate between typical antipsychotic and
narcotic motor dysfunction, atropine may be given as a conjunctive treatment. In the
case of typical antipsychotic-induced catalepsy, atropine acts as an antagonist to this
effect, while narcotic-induced catatonia is not affected by atropine treatment (Costall
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& Naylor, 1974). This evidence supports the idea that catalepsy, and therefore EPS,
occurs due to a deficiency in dopamine function induced by chronic dopamine
receptor antagonism in the form of typical antipsychotic treatment.
Although the catalepsy test cannot discriminate between atypical and typical
antipsychotic drugs or narcotic-induced catatonia, it has high predictive validity for
detecting EPS liability in humans. Positron emission tomography has been used by
Wadenberg, Kapur, Soliman, Jones, and Vaccarino (2000) to show that antipsychotic
drug doses that caused EPS in humans correlate with doses that caused catalepsy in
rats.
Paw test
The paw test was developed as an alternative to the catalepsy test, which was
ineffective in evaluating atypical antipsychotics such as clozapine that have a low
EPS liability. The paw test measures muscle rigidity and compares the retraction
times of both the fore- and hindlimbs of the rat. Ellenbroek, Peeters, Honig, and
Cools (1987) found that typical antipsychotics inhibit forelimb and hindlimb
retraction at equivalent doses, while atypical antipsychotics inhibit hindlimb
retraction at lower doses more strongly than forelimb retraction. Furthermore, an
increase in forelimb retraction time is correlated with increased catalepsy, thus
predicting extrapyramidal symptom liability. The paw test is therefore an effective
research tool not only for identifying potential typical antipsychotics, but also for
differentiating between typical and atypical antipsychotic activity.
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Prepulse inhibition (PPI)
Prepulse inhibition is purported to be a measure of sensorimotor gating,
wherein a pre-pulse inhibits, or gates, the startle response to a stronger stimuli that
immediately follows the pre-pulse. Therefore, deficits in PPI indicate a deficit in
sensorimotor gating, which is linked to activity in the forebrain (Braff et al., 2001).
PPI does not require training, as it occurs on the first exposure to pre-pulse and pulse
stimuli (Blumenthal, Schicatano, Chapman, Norris, & Ergenzingerm, 1996), and can
also be studied across species (Braff et al., 2001). In a review of clinical literature in
schizophrenic patients, Braff, Geyer, and Swerdlow (2001) found deficits in pre-pulse
inhibition (PPI) were consistently noted. Specifically, patients with early-onset
schizophrenia have the most significant deficits in PPI (Kumari, Soni, Mathew, &
Sharma, 2000).
Initial studies relating dopaminergic activity to PPI in rats found that
stimulation of dopamine D2 receptors inhibits PPI. This effect is attenuated by the
administration of the dopamine D2 receptor antagonist, haloperidol. Haloperidol
alone, however, has no effect on PPI (Mansbach, Geyer, & Braff, 1988). Results
from this study further supported the hypothesis that the symptoms of schizophrenia
manifest as a result of overactivity of dopaminergic systems. The use of PPI in
animals, however, does not appear to always be effective as a screening tool for
antipsychotic agents in the absence of the pharmacological stimulation of dopamine
activity. Phencycladine-induced PPI deficits, which manifest through glutamatergic
activity, however, may reliably differentiate between typical and atypical
antipsychotic drugs (see Geyer & Ellenbroek, 2003 for review). In human studies,
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chronic treatment with typical antipsychotics, but not atypical antipsychotics,
correlates with a reduction in PPI as compared to healthy controls (Kumari et al.,
2000), suggesting that PPI may be useful as a tool for screening potential
antipsychotic drugs in the case of chronic administration of experimental compounds,
but not with acute drug administration.
Microdialysis
Detecting changes in neurotransmission in response to antipsychotic treatment
is achieved through microdialysis. Researchers measure the activity in specific brain
regions by inserting a microdialysis probe into a region of interest by stereotaxic
surgery. Extracellular fluid is then sampled via the microdialysis probe and analyzed
using high pressure liquid chromatography. Rollema and colleagues (1997) have
demonstrated that clozapine increases dopamine levels in the prefrontal cortex. This
area has been implicated in the negative symptoms and cognitive impairments of
schizophrenia. Typical antipsychotic drugs increase dopamine levels in the striatum.
Increases in dopamine in the striatum over the prefrontal cortex is thought to underlie
the development of extrapyramidal symptoms as well as the aggravation of negative
symptoms in schizophrenia (Kuroki, Meltzer, & Ichikawa, 1999). Therefore,
experimental compounds that are evaluated pre-clinically for the treatment of
schizophrenia would be expected to increase prefrontal cortical dopamine levels,
while having little to no effect on dopamine levels in the striatum.
Conditioned Avoidance Response (CAR)
The conditioned avoidance response (CAR) task has been used to preclinically identify every known antipsychotic drug to date. In the CAR task, animals
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are trained to avoid a noxious stimuli (e.g., a foot shock) by responding to a warning
stimulus (e.g., a white noise) which precedes the noxious stimuli. Antipsychotic
drugs reduce avoidance responding in the CAR task without inhibiting escape
responses. Drugs that induce catalepsy or act as tranquilizers reduce avoidance and
escape responses in the CAR task. That is, animals fail to respond to both the
warning stimulus and the noxious stimuli. Tranquilizers, unlike antipsychotics, will
persistently produce escape failures even when the shock stimulus is increased
(Grilly, Johnson, Minardo, Jacoby, & LaRiccia, 1984). Both typical and atypical
antipsychotics inhibit CAR, however, typical antipsychotics are far more potent in
this regard, and the mechanism by which avoidance responses are decreased is
hypothesized to be a result of dopamine D 2 receptor blockade. Further support for
this hypothesis has been shown by the use of amphetamine, which restores
antipsychotic-induced deficits in the CAR (Taboada, Souto, Hawkins, & Monti,
1979). Because both typical and atypical antipsychotic drugs have the potential to
produce deficits in CAR, this task is inappropriate for differentiating typical from
atypical antipsychotic drugs. Research using positron emission tomography in
humans, as well as in vivo binding in rats, confirms that typical antipsychotic doses
that produce CAR in rats have similar levels of dopamine receptor binding as those
that have efficacy in humans. Also, doses that produce escape failures in CAR, a
measure indicative of catalepsy, produce EPS in humans at similar levels of
dopamine receptor occupancy (Wadenberg, Kapur et al., 2000).
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Idazoxan and CAR
Hertel et al. (1999) found that idazoxan enhanced the effects of the typical
antipsychotic, raclopride, in the CAR task and also potentiated raclopride-induced
dopamine release in the prefrontal cortex. Wadenberg and colleagues (2007) have
lent further support to the α2/D2 hypothesis of atypicality using idazoxan in the CAR
task. Idazoxan enhanced the suppression of CAR when paired with a subthreshold
dose of haloperidol as well as with a low dose of olanzapine. Idazoxan also reversed
catalepsy induced by haloperidol, and potentiated haloperidol-induced dopamine
increases in the prefrontal cortex, but not the nucleus accumbens. The use of α2
adrenoceptor agonists in CAR was ineffective in restoring avoidance, rather,
avoidance responses were decreased through this treatment, further suggesting that
blockade of α2 receptors contributes to an antipsychotic drug profile (Taboada et al.,
1979).
Rationale
Because the α2/D2 hypothesis of atypicality has been supported nearly entirely
by studies utilizing idazoxan as an α2 adrenoceptor antagonist, there is a need to
explore this hypothesis using other α2 antagonists. Because idazoxan has been found
to act as an agonist at 5-HT1A receptors, it is unclear whether the action of α2
adrenoceptor blockade is responsible for the antipsychotic action of idazoxan (Llado,
Esteban, & Garcia-Sevilla, 1996).
These studies sought to determine if drugs that block of α2 and D2 receptors
block a conditioned avoidance response, and if the effects of idazoxan at 5-HT1A
receptors may mediate antipsychotic effects. To test this hypothesis, a series of
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compounds selective for α2, D2 and 5-HT1A receptors were tested in the conditioned
avoidance response task. First, the effects of dopamine D2 receptor antagonism alone
in the CAR task were evaluated. Dopamine D2 receptor antagonists were then paired
with an α2 adrenoceptor antagonist to determine whether this combination would
produce an antipsychotic effect in the CAR task. To block the 5-HT1A receptor
agonist properties of idazoxan, a 5-HT1A receptor antagonist was given with the
combined treatment of the D2 receptor antagonist and idazoxan. The D 2 receptor
antagonist and idazoxan treatment was also given in combination with an α 2
adrenoceptor agonist, in order to block the α 2 adrenoceptor antagonistic properties of
idazoxan. A dopamine D2 receptor antagonist was paired with a 5-HT1A receptor
agonist to determine whether combined dopamine D 2 receptor antagonism and 5HT1A receptor agonism is sufficient for producing an antipsychotic effect. It was
hypothesized that 5-HT1A agonism mediates the effects of idazoxan and a dopamine
D2 antagonist in the conditioned avoidance response task in rats.
Methods
Animals
Adult male Sprague-Dawley rats (Charles River, Inc, Portage, MI) were group
housed in the Psychology Department rodent colony at Northern Michigan University
for at least one week prior to experimental procedures. Animals’ food rations were
monitored so that excessive weight gain did not occur during the course of the study.
Animals were not allowed to drop below 95% of their starting weight or exceed their
healthy starting weight. The colony temperature and humidity were regulated with a
12 hour light/dark cycle (lights on at 7:00 a.m.). Rats had free access to water at all
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times. All procedures were approved by the Northern Michigan University
Institutional Animal Care and Use Committee (IACUC #094) and are consistent with
the “Guide for the Care and Use of Laboratory Animals” (National Research Council,
1996).
For the studies, eight subjects per group (16 subjects total) were sufficient to
detect statistically significant effects (power = 0.80, α = 0.05) given a medium
magnitude of treatment effect (e.g., effect size = 0.30)(Jaccard and Becker, 1999,
Statistics for the Behavioral Sciences). These studies used a blocked within-subjects
research design, meaning that subjects served as their own experimental controls in 1
of 2 different treatment blocks. Dividing animals among the treatment blocks
minimized discomfort by limiting the number of injections and test sessions to which
the animals were exposed. Because 20% of subjects often fail to learn the procedures
of the task, 20 subjects total (10 subjects per group) were used to insure that an
adequate sample size would be available after the estimated failure rate.
Apparatus
A standard rat shuttle avoidance chamber with a tilting shock grid floor and
guillotine dividing door was used for the Conditioned Avoidance Response task (Med
Associates, model #ENV-010MC; 20.3 x 15.9 x 21.3 cm). The avoidance chamber
was housed in a sound-attenuating chamber fixed with an exhaust fan which was on
throughout all procedures to provide ventilation as well as to mask environmental
noise. The apparatus was programmed and data was collected and recorded using
MedPC software (version IV) provided by Med Associates.
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Conditioned Avoidance Response
The procedures for conditioned avoidance response have been previously
described (Wadenburg et al., 1998; Wadenburg et al., 2006). At the presentation of
80-dB white noise, animals had 10 seconds to move into the adjacent compartment of
the shuttlebox. As this has a two-way avoidance procedure, animals could make an
avoidance response from either side of the shuttlebox. If the rat remained for more
than 10 seconds, a brief, low-intensity shock (0.3-0.5 mA of 0.5 second duration) was
administered to the grid floor every 2.5 seconds until the rat escaped to the other
compartment. However, if the rat failed to escape to the other compartment within 60
seconds, then the intermittent shock delivery was terminated (i.e., an escape failure)
and the test session was terminated. Trials began at the onset of the white noise
warning and were terminated when either 1) the rat successfully avoided the shock by
crossing over into the adjacent compartment, 2) the rat failed to avoid the shock, but
escaped the shock by crossing over to the adjacent compartment or 3) the rats failed
to escape the shock after 60 seconds. The interval between trials varied randomly
between 20 and 40 seconds. From this task, the behavioral variables of avoidance,
escape, escape failure, before session crosses, and intertrial crosses were recorded by
the MedPC software used to control the shuttlebox. Antipsychotic effects manifest as
avoidance failures in the conditioned avoidance response task. That is, animals fail to
move into the adjacent compartment at the presentation of the white noise. Instead,
animals move to the adjacent compartment only when the shock is delivered. This
failure is distinct from an escape failure wherein the shock fails to elicit an escape
response and the animal remains in the chamber until the test session is terminated.
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Escape failures are associated with tranquilizing effects or motor effects rather than
antipsychotic effects.
Training
Animals were trained in the conditioned avoidance response task in daily
sessions lasting 15 minutes, until a 90% successful avoidance rate was achieved over
3 consecutive sessions. The training session trials were identical to the procedures
described above. Each training session consisted of 17 to 27 trials. Intertrial intervals
varied randomly (VI 40).
Testing
Following completion of training, animals were given a 2 to 3 day rest period
prior to the first test session. Afterwards, test sessions were conducted for one day
followed by one day of rest and one day of training to ensure that drugs were no
longer present from the previous test sessions. Thus, 2 test sessions and 2 training
sessions were conducted per animal per week. At the beginning of each test day, all
rats were given a 10 minute pretest session prior to drug or vehicle administration to
insure that the animals were still performing the task accurately (at a 90% successful
avoidance rate). Animals that failed to meet pretest criteria were not injected and
given a day of rest, followed by additional training sessions as needed. After the
pretest session, rats were given a subcutaneous injection of drug or vehicle, and then,
after a 30 minute delay, a 10 minute test session consisting of 15 to 20 trials was
conducted. The pretest and test session trials are identical to the procedures described
above.
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Treatments
Animals were assigned to one of two treatment blocks and received all
treatments within their assigned block.
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Table 2. Treatment blocks for 2 animal groups in the conditioned avoidance response
task with the receptor mechanisms involved in drug action. Treatment orders were
randomly assigned to each animal, with animals receiving all treatments within their
assigned block. RAC = raclopride, HAL = haloperidol, IDX = idazoxan, YOH =
yohimbine, WAY = WAY100635, GF = guanfacine, block = receptor blockade;
antagonism, stim = receptor stimulation; agonism.
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Table 2. Treatment groups for 2 animal groups in the conditioned avoidance response
task. Treatments were randomized within groups.
TREATMENT GROUP

RECEPTOR AFFINITY

GROUP 1
Dose response curves for all drugs

-

Vehicle

-

RAC + 8-OH-DPAT

D2 block + 5-HT1A stim

RAC + IDX + GF

D2 block + α2 block + α2 stim

GROUP 2
RAC + IDX

D2 block + α2 block

HAL + IDX

D2 block + α2 block

RAC + YOH

D2 block + α2 block

RAC + IDX + WAY

D2 block + α2 block + 5-HT1A block

Treatment group one included dose-response curves for all compounds as
well as one combination treatment aimed at exploring the possible role of 5-HT1A
agonism in antipsychotic action, along with the appropriate vehicle control groups.
Treatment group two consisted of the α2/D2 combination groups, including the
appropriate vehicle controls. Treatment group two also received a three-part
treatment combination aimed at reversing the effects of the α2/D2 combination, along
with the appropriate vehicle controls. Animals in both treatment groups were
randomly assigned a treatment order within their block. Each treatment block was
designed to have approximately the same number of treatments. All drugs, except
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haloperidol and yohimbine, were dissolved in 0.9% saline. Haloperidol and
yohimbine were dissolved in distilled water with a few drops of lactic acid and
buffered back to a pH of 7 with sodium hydroxide.
The initial experiments performed in animal group 1 sought to identify an
effective dose of a typical antipsychotic drug for reducing avoidance responding in
the conditioned avoidance response task (CAR). Sub-effective (doses that fail to
reduce CAR) and cataleptic (doses that result in escape failures) were also identified.
Animals were randomly assigned the dose-response curves for the D2 antagonists
raclopride (0.025mg/kg, 0.05mg/kg, 0.075mg/kg) and haloperidol (0.0125mg/kg,
0.025mg/kg, 0.05mg/kg). To illustrate that α2 adrenoceptor blockade alone does not
produce an antipsychotic effect, both idazoxan (1.5mg/kg and 3.0mg/kg) and
yohimbine (1.0mg/kg, 2.0mg/kg) were tested alone in the CAR task. Both a saline
and a distilled water vehicle control were tested.
Once a dose-response curve was completed for raclopride and haloperidol,
these drugs were paired with idazoxan in treatment group 2 to demonstrate that α2/D2
receptor blockade produces deficits in avoidance responding. Raclopride was also
administered with the α2 adrenoceptor antagonist, yohimbine, to further generalize the
previous results. Therefore, previous studies using raclopride, haloperidol and
idazoxan were replicated, and these results were generalized to the α2 adrenoceptor
antagonist, yohimbine. Appropriate vehicle controls for all treatment combinations
were included in this treatment block. Animals were randomly assigned to a
treatment schedule.
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Treatment group two was also administered the 5-HT1A antagonist,
WAY100635 (WAY), with the raclopride/idazoxan combination. A very low dose of
WAY (0.05mg/kg) as well as a higher dose (0.2mg/kg) was tested to explore the
cataleptic effects of 5-HT1A blockade when administered with the raclopride/idazoxan
combination. Appropriate vehicle controls for these three-part combinations were
included in this treatment block. Treatment group one received a three-part treatment
combination to block the α2 adrenoceptor component of idazoxan. This was achieved
through the use of guanfacine (0.8mg/kg), an α2 adrenoceptor agonist.
Finally, treatment group one included a combination treatment of a subeffective dose of raclopride and the 5-HT1A agonist, (+)8-OH-DPAT (0.04mg/kg and
0.08mg/kg) as well as the appropriate vehicle controls for this combination.
Data Analysis
Data were analyzed using GraphPad Prism version 5.01 (GraphPad Software,
Inc., La Jolla, CA). Percent avoidance, percent escape, intertrial crosses and escape
failures were obtained after every training, pretesting, and testing session. Percent
values were calculated by dividing the number of avoidance or escape responses by
the total number of trials. Percent avoidance, percent escape, and intertrial crosses for
treatments within groups were compared using a repeated measures one-way analysis
of variance (ANOVA) followed by a Tukey’s multiple comparison test post-hoc
analysis. Escape failures were analyzed using a Friedman test followed by Dunn’s
multiple comparison post-hoc analysis. Nonparametric analyses were used to
evaluate escape failures, as only one escape failure could occur during each test
session.
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Results
Training
Of the 20 rats used in this study, 16 met the training criteria. Four animals
were eliminated from the study after failing to meet training criteria following 30
days of training. Animals that had an escape failure on the first training day were
given additional training wherein the experimenter moved the animal into the other
compartment at the presentation of the white noise to facilitate responding. This
training was discontinued when the animal had avoidance responses on three
successive trials. Seven animals had escape failures during the first training session,
while the remaining nine completed training without having escape failures. The
animals that were retained for the study had 3 successive training periods of 90%
avoidance response or better after an average of 7.3 days of training (+/- 2.1 standard
error of the mean (SEM); Figure 1).
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Figure 1. Acquisition of conditioned avoidance responding shown as mean percent
avoidance responding (+/- SEM) over 12 consecutive training days for animals in the
conditioned avoidance response task. Numbers in parentheses indicate N, otherwise,
N = 16.
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Figure 1. Conditioned avoidance response training over 12 consecutive training days.
Numbers in parentheses indicate N, otherwise, N = 16.
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Testing
Dose Response Curves
Raclopride
The data for avoidance responding for raclopride (RAC; 0.025, 0.05, and
0.075 mg/kg) are shown in figure 2. Data for percent escape, escape failures and
intertrial crosses for raclopride are shown in table 3. RAC reduced avoidance
responding in a dose-dependent manner (F(3, 21) = 20.29, p<0.0001). RAC 0.05
mg/kg produced significantly lower percent avoidance than SAL (p<0.01). RAC
0.075 mg/kg also reduced avoidance significantly compared to SAL (p<0.001) as
well as RAC 0.05 mg/kg (p<0.05). Percent escape increased in a dose-dependent
manner (F(3, 21) = 20.94, p<0.0001). RAC 0.05 mg/kg produced significantly
greater percent escape than SAL (p<0.05) and RAC 0.075 mg/kg produced
significantly greater escape responses than SAL (p<0.0001). RAC 0.075 mg/kg
produced significantly more escape responses than RAC 0.05 mg/kg (p<0.05).
Escape failures were not significantly different overall (insert χ2(3) = 4.800, p =
0.1870). Intertrial crosses differed significantly overall (F(3, 21) = 39.43, p<0.0001),
with all doses of RAC having significantly fewer intertrial crosses than SAL.
Haloperidol
The data for avoidance responding for haloperidol (HAL; 0.0125, 0.025, and
0.05 mg/kg) are shown in figure 3. Data for percent escape, escape failures and
intertrial crosses for HAL are shown in table 4. HAL reduced avoidance responding
in a dose-dependent manner (F(3, 21) = 19.47, p<0.0001). HAL 0.025 mg/kg and
HAL 0.05 mg/kg produced significantly greater avoidance responding than H20/LAC
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(p<0.01). HAL increased escape responses in a dose-dependent manner (F(3, 21) =
34.59, p<0.0001). HAL 0.025 mg/kg and HAL 0.05 mg/kg produced significantly
more escape responses than H20/LAC (p<0.001). HAL 0.025 mg/kg and HAL 0.05
mg/kg were no different in either percent avoidance or percent escape. There was an
overall significance for number of escape failures across groups (χ2(3) = 14.76,
p<0.01), however, Dunn’s multiple comparisons post-hoc analysis found no
significant difference between treatments. Overall, the number of intertrial crosses
between groups was significant (F(3, 21) = 35.82, p<0.0001), with all HAL
treatments having significantly fewer crosses than H20/LAC (p<0.001).
Idazoxan
The data for avoidance responding for idazoxan (IDX; 1.5 and 3.0 mg/kg) are
shown in figure 4. Data for percent escape, escape failures and intertrial crosses for
IDX are shown in table 5. No statistical difference in percent avoidance was found
between either IDX treatment and SAL (F(2, 14) = 1.136, p = 0.3490). Intertrial
crosses differed significantly overall (F(2, 14) = 5.081, p<0.05), with both IDX
treatments having fewer crosses than SAL (p<0.05). Each dose of IDX produced one
escape failure.
Yohimbine
The data for avoidance responding for yohimbine (YOH; 1.0 and 2.0 mg/kg)
are shown in figure 5. Data for percent escape, escape failures and intertrial crosses
for YOH are shown in table 6. No significant difference in percent avoidance was
found between either YOH treatment and SAL (F(2, 14) = 0.4667, p=0.6365), and no
treatment had escape failures. No significant differences in intertrial crosses were
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found between either YOH treatment and SAL (F(2, 14) = 0.2946, p = 0.7493).
Neither dose of YOH produced escape failures.
WAY100635
The data for avoidance responding for WAY100635 (WAY; 0.05 and 0.2
mg/kg) are shown in figure 6. Data for percent escape, escape failures and intertrial
crosses for WAY are shown in table 7. WAY and SAL did not differ significantly in
percent avoidance (F(2, 14) = 1.862, p = 0.1918). Intertrial crosses differed
significantly across treatments (F(2, 14) = 7.527, p<0.01) with WAY 0.05 mg/kg
producing significantly fewer crosses than SAL (p<0.05) and WAY 0.2 mg/kg having
significantly fewer crosses than SAL (p<0.01). Neither dose of WAY produced
escape failures
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Figure 2. Mean percent avoidance responding (+/- SEM) for raclopride (RAC)
0.025, 0.05, and 0.075 mg/kg and saline. RAC 0.05 mg/kg produced significantly
lower percent avoidance than saline (*p<0.05). RAC 0.075 mg/kg produced
significantly lower percent avoidance than saline (**p<0.01).
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Figure 2. Mean percent avoidance responding (+/- SEM) for raclopride.
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Table 3. Mean percent escape responding, number of escape failures and mean
intertrial crosses for raclopride (RAC) 0.025, 0.05, and 0.075 mg/kg and saline
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Treatment

Escape

Intertrial

Failures

Crosses

0

17.8

RAC 0.025 mg/kg 17.6

0

3.1

RAC 0.05 mg/kg

45.5

2

0.1

RAC 0.075 mg/kg 80.4

2

0

Saline

%Escape

0

Table 3. Mean percent escape, number of escape failures and intertrial crosses for
raclopride.

44

Figure 3. Mean percent avoidance responding (+/- SEM) for haloperidol (HAL)
0.0125, 0.025, and 0.05 mg/kg and vehicle (H20/LAC). HAL 0.025 and 0.05 mg/kg
had significantly lower percent avoidance than H 20/LAC (***p<0.001).
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Figure 3. Mean percent avoidance responding (+/- SEM) for haloperidol.
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Table 4. Mean percent escape responding, number of escape failures and mean
intertrial crosses for haloperidol 0.0125, 0.025, and 0.05 mg/kg and vehicle
(H20/LAC).
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Treatment

%Escape

Escape

Intertrial

Failures

Crosses

H20/LAC

0

0

14.9

HAL 0.0125 mg/kg

0.8

0

4.1

HAL 0.025 mg/kg

69.9

5

0

HAL 0.05 mg/kg

64.8

6

0

Table 4. Mean percent escape, number of escape failures and intertrial crosses for
haloperidol.
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Figure 4. Mean percent avoidance responding (+/- SEM) for idazoxan (IDX) 1.5 and
3.0 mg/kg and saline.
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Figure 4. Mean percent avoidance responding (+/- SEM) for idazoxan.

50

Table 5. Shows mean percent escape responding, number of escape failures, and
mean intertrial crosses for idazoxan (IDX) 1.5 and 3.0 mg/kg and saline.

51

Treatment

%Escape

Escape

Intertrial

Failures

Crosses

Saline

0

0

17.8

IDX 1.5 mg/kg

0

1

11.5

IDX 3.0 mg/kg

0.7

1

11.5

Table 5. Mean percent escape, number of escape failures and intertrial crosses for
idazoxan.
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Figure 5. Shows mean percent avoidance responding (+/- SEM) for yohimbine
(YOH) 1.0 and 2.0 mg/kg and vehicle (H20/LAC).
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Figure 5. Mean percent avoidance responding (+/- SEM) for yohimbine.
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Table 6. Mean percent escape responding, number of escape failures and mean
number of intertrial crosses for yohimbine (YOH) 1.0 and 2.0 mg/kg.
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Treatment

%Escape

Escape

Intertrial

Failures

Crosses

H20/LAC

0

0

14.9

YOH 1.0 mg/kg

0.7

0

18

YOH 2.0 mg/kg

0.7

0

16.4

Table 6. Mean percent escape, number of escape failures and intertrial crosses for
yohimbine.
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Figure 6. Mean percent avoidance responding (+/- SEM) for WAY100635 (WAY)
0.05 and 0.2 mg/kg and saline.
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Figure 6. Mean percent avoidance responding (+/- SEM) for WAY100635.
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Table 7. Mean percent escape responses, number of escape failures and mean number
of intertrial crosses for WAY100635 (WAY) 0.05 and 0.2 mg/kg and saline.
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Treatment

%Escape

Escape

Intertrial

Failures

Crosses

Saline

0

0

17.8

WAY 0.05 mg/kg

2.3

0

10.6

WAY 0.2 mg/kg

0.8

0

9.9

Table 7. Mean percent escape, number of escape failures and intertrial crosses for
WAY100635.
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Paired Treatments
Raclopride + Idazoxan
The data for avoidance responding for RAC+IDX (RAC = 0.025 mg/kg, IDX
= 1.5 mg/kg) are shown in figure 7. Data for percent escape, escape failures and
intertrial crosses for RAC+IDX are shown in table 8. Percent avoidance differed
significantly across treatments (F(3, 21) = 11.63, p<0.0001). The vehicle controls did
not differ significantly from one another. RAC+IDX produced lower percent
avoidance than RAC+SAL (p<0.01), IDX+SAL (p<0.001) and SAL+ SAL (p<0.001).
Percent escape differed significantly across treatments (F(3, 21) = 10.84, p<0.001).
RAC+IDX produced significantly more escape responses than SAL+SAL (p<0.001),
IDX+SAL (p<0.001), and RAC+SAL (p<0.05). Number of escape failures did not
differ significantly across treatments (χ2(3) = 6.000, p = 0.116). Intertrial crosses
differed significantly across groups (F(3, 21) = 10.13, p<0.001). RAC+IDX
produced significantly fewer crosses than IDX+SAL (p<0.001).
Raclopride + Yohimbine
The data for avoidance responding for RAC+YOH (RAC = 0.025 mg/kg,
YOH = 1.0 or 2.0 mg/kg) are shown in figure 8. Data for percent escape, escape
failures and intertrial crosses for RAC+YOH are shown in table 9. Percent avoidance
differed significantly overall (F(5, 35) = 11.69, p<0.0001). RAC+YOH 1.0 mg/kg
produced significantly lower percent avoidance than SAL+H20/LAC and SAL+YOH
1.0 mg/kg (p<0.05). RAC+YOH 2.0 mg/kg produced significantly lower percent
avoidance than SAL+H20/LAC (p<0.001) and SAL+YOH 2.0 mg/kg (p<0.001)
Percent escape also differed significantly overall (F(5, 35) = 11.38, p<0.0001) with
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RAC+YOH 1.0mg/kg producing significantly more escape responses than
SAL+H20/LAC and SAL+YOH 1.0 mg/kg (p<0.05). RAC+YOH 2.0 mg/kg
produced significantly more escape responses than SAL+H20/LAC (p<0.001) and
SAL+YOH 2.0 mg/kg (p<0.001). Number of intertrial crosses differed significantly
overall (F(5, 35) = 8.709, p<0.0001). RAC+YOH 1.0 mg/kg produced significantly
fewer intertrial crosses than SAL+YOH 1.0 mg/kg (p<0.05) and RAC+YOH 2.0
mg/kg produced significantly fewer intertrial crosses than SAL+YOH 2.0 mg/kg
(p<0.001).
Haloperidol + Idazoxan
The data for avoidance responding for HAL+IDX (HAL = 0.0125 mg/kg, IDX
= 1.5 mg/kg) are shown in figure 9. Data for percent escape, escape failures and
intertrial crosses for HAL+IDX are shown in table 10. Percent avoidance was
significant overall (F(5, 35) = 2.734, p<0.05), however, post-hoc analysis found no
significant differences between pairs. Percent escape was significant overall (F(5, 35)
= 2.585, p<0.05), however, post-hoc analysis found no significant differences
between pairs. Intertrial crosses did not differ significantly overall (F(5, 35) = 1.310,
p=0.2825).
Raclopride + 8-OH-DPAT
The data for avoidance responding for RAC+8-OH-DAPT (RAC = 0.025
mg/kg, 8-OH-DPAT (DPAT) = 0.04 or 0.08 mg/kg) are shown in figure 10. Data for
percent escape, escape failures and intertrial crosses for RAC+DPAT are shown in
table 11. Avoidance responding differed significantly across treatments (F(6, 42) =
75.74, p<0.0001) with RAC+DPAT 0.04 mg/kg producing significantly lower percent
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avoidance than SAL+DPAT 0.04 mg/kg and DPAT 0.04 mg/kg (p<0.001).
RAC+DPAT 0.08 mg/kg produced significantly lower percent avoidance than
SAL+DPAT 0.08 mg/kg and DPAT 0.08 mg/kg (p<0.001). Percent escape differed
significantly overall (F(6, 42) = 31.57, p<0.0001). RAC+DPAT 0.04 mg/kg
produced significantly more escape responses than SAL+DPAT 0.04 mg/kg and
DPAT 0.04 mg/kg (p<0.001) and RAC+DPAT 0.08 mg/kg produced significantly
more escape responses than SAL+DPAT 0.08 mg/kg and DPAT 0.08 mg/kg
(p<0.001). Escape failures differed significantly overall (χ2(6) = 24.00, p<0.001),
however, post-hoc analysis did not find any significant differences between pairs.
Intertrial crosses differed significantly overall (F(6, 42) = 12.63, p<0.0001).
RAC+DPAT 0.04 mg/kg produced significantly fewer intertrial crosses than
SAL+DPAT 0.04 mg/kg and DPAT 0.04 mg/kg (p<0.001). RAC+DPAT 0.08 mg/kg
produced significantly fewer intertrial crosses than SAL+DPAT 0.08 mg/kg (p<0.01)
and DPAT 0.08 mg/kg (p<0.001).
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Figure 7. Mean percent avoidance responding for raclopride (0.025 mg/kg) +
idazoxan (1.5 mg/kg) and saline contol (SAL). RAC+IDX had significantly lower
percent avoidance than SAL+SAL (***p<0.001) and RAC+SAL (##p<0.01).
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Figure 7. Mean percent avoidance responding (+/- SEM) for raclopride + idazoxan.
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Table 8. Mean percent escape responses, number of escape failures and mean number
of intertrial crosses for raclopride (0.025 mg/kg) + idazoxan (1.5 mg/kg) (RAC+IDX)
and vehicle controls (SAL = saline).
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Treatment

%Escape

Escape

Intertrial

Failures

Crosses

SAL+SAL

0

0

9.5

SAL+IDX

1.5

0

15

RAC+SAL

16.9

0

3

RAC+IDX

56

2

2.6

Table 8. Mean percent escape, number of escape failures and intertrial crosses for
raclopride + idazoxan.
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Figure 8. Mean percent avoidance responding (+/- SEM) for raclopride (0.025 mg/kg)
+ yohimbine (1.0 and 2.0 mg/kg) (RAC+YOH) and vehicle controls (SAL = saline,
H20/LAC = water and lactic acid). RAC+YOH 1.0 mg/kg had significantly lower
percent avoidance than SAL+H20/LAC (*p<0.05) and SAL+YOH 1.0 mg/kg
(#p<0.05). RAC+YOH 2.0 mg/kg had significantly lower percent avoidance than
SAL+H20/LAC (***p<0.001) and SAL+YOH 2.0 mg/kg (###p<0.001).
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Figure 8. Mean percent avoidance responding (+/- SEM) for raclopride + yohimbine.
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Table 9. Mean percent escape responding, number of escape failures and mean
number of intertrial crosses for raclopride (0.025 mg/kg) + yohimbine (1.0 and 2.0
mg/kg) and vehicle controls (SAL = saline, H20/LAC = water with lactic acid).
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Treatment

%Escape

Escape

Intertrial

Failures

Crosses

SAL+H20/LAC

0

0

11.9

RAC+H20/LAC

29.7

0

2.5

SAL+YOH 1.0 mg/kg

0

0

13.3

RAC+YOH 1.0 mg/kg

32.6

0

2.8

SAL+YOH 2.0 mg/kg

0

0

16.5

RAC+YOH 2.0 mg/kg

60.5

2

1.6

Table 9. Mean percent escape, number of escape failures and intertrial crosses for
raclopride + yohimbine.
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Figure 9. Mean percent avoidance (+/- SEM) for haloperidol (0.0125 mg/kg) +
idazoxan (1.5 mg/kg) (HAL+IDX) and vehicle controls (SAL = saline, H 20/LAC =
water and lactic acid).
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Figure 9. Mean percent avoidance responding (+/- SEM) for haloperidol + idazoxan.
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Table 10. Mean percent escape, number of escape failures and mean number of
intertrial crosses for haloperidol (0.0125 mg/kg) + idazoxan (1.5 mg/kg) (HAL+IDX)
and vehicle controls (SAL = saline, H20/LAC = water with lactic acid).
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Treatment

%Escape

Escape

Intertrial

Failures

Crosses

SAL+H20/LAC

0

0

11.9

H20/LAC+IDX 1.5 mg/kg

3.8

0

11.5

H20/LAC+IDX 3.0 mg/kg

0

0

17.5

HAL+SAL

0.7

0

10.3

HAL+IDX 1.5 mg/kg

8.0

0

11.1

HAL+IDX 3.0 mg/kg

0.8

0

12.3

Table 10. Mean percent escape, number of escape failures and intertrial crosses for
haloperidol + idazoxan.
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Figure10. Mean percent avoidance (+/- SEM) for raclopride (0.025 mg/kg) + 8-OHDPAT (0.04 and 0.08 mg/kg) (RAC+DPAT) and vehicle controls (SAL = saline).
RAC+DPAT 0.08 mg/kg had significantly lower percent avoidance than SAL+SAL
(***p<0.001) and SAL+DPAT 0.08 mg/kg (###p<0.001). RAC+DPAT 0.04 mg/kg
had significantly lower percent avoidance than SAL+SAL (***p<0.001) and
SAL+DPAT 0.04 mg/kg (###p<0.001).
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Figure 10. Mean percent avoidance responding (+/- SEM) for raclopride + (+)
8-OH-DPAT.
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Table 11. Mean percent escape responding, number of escape failures and mean
number of intertrial crosses for raclopride (0.025 mg/kg) + 8-OH-DPAT (0.04 and
0.08 mg/kg) (RAC+DPAT) and vehicle controls (SAL = saline).
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Treatment

%Escape

Escape

Intertrial

Failures

Crosses

SAL+SAL

0

0

12.1

DPAT 0.08 mg/kg

2.8

0

13.9

DPAT 0.08 mg/kg+SAL

6.7

0

12.4

RAC+DPAT 0.08 mg/kg

73.5

4

0.4

DPAT 0.04 mg/kg

0

0

15

DPAT 0.04 mg/kg+SAL

0

0

16.6

RAC+DPAT 0.04 mg/kg

61.3

4

0.3

Table 11. Mean percent escape, number of escape failures and intertrial crosses for
raclopride + (+)8-OH-DPAT.

79

Three Part Combinations
Raclopride + Idazoxan + WAY100635(0.05 mg/kg)
The data for avoidance responding for RAC+IDX+WAY (RAC = 0.025
mg/kg, IDX = 1.5 mg/kg, WAY = 0.05 mg/kg) are shown in figure 11. Data for
percent escape, escape failures and intertrial crosses for RAC+IDX+WAY are shown
in table 12. Avoidance responses differed significantly overall (F(5, 35) = 17.98,
p<0.0001). RAC+IDX+WAY produced significantly lower avoidance responding
than SAL+SAL+WAY (p<0.001), RAC+SAL+WAY (p<0.05), and
SAL+IDX+WAY (p<0.001). RAC+SAL+WAY produced significantly lower
percent avoidance than SAL+IDX+WAY (p<0.05) and SAL+SAL+WAY (p<0.05).
RAC+IDX produced significantly lower percent avoidance than SAL+SAL+WAY
(p<0.001) and SAL+IDX+WAY (p<0.001).
Escape responses differed significantly overall (F(5, 35) = 17.08, p<0.0001).
RAC+IDX+WAY produced significantly more escape responses SAL+SAL+WAY
(p<0.001), RAC+SAL+WAY (p<0.05), and SAL+IDX+WAY (p<0.001), and
SAL+SAL+SAL (p<0.001). RAC+SAL+WAY produced significantly more escape
responses than SAL+SAL+WAY (p<0.01), and SAL+IDX+WAY (p<0.01).
RAC+IDX produced significantly more escape responses than SAL+IDX+WAY
(p<0.001), and SAL+SAL+WAY (p<0.001). Number of escape failures did not differ
significantly across treatments (χ2(5) = 10.00, p = 0.0752). Intertrial crosses differed
significantly across treatments (F(5, 35) = 9.249, p<0.0001) with RAC+IDX+WAY
producing significantly fewer crosses than SAL+SAL+SAL (p<0.001), and
SAL+SAL+WAY (p<0.001).
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Raclopride + Idazoxan + WAY100635(0.2 mg/kg)
The data for avoidance responding for RAC+IDX+WAY (RAC = 0.025
mg/kg, IDX = 1.5 mg/kg, WAY = 0.2 mg/kg) are shown in figure 12. Data for
percent escape, escape failures and intertrial crosses for RAC+IDX+WAY are shown
in table 13. Avoidance responses differed significantly overall (F(5, 35) = 17.64,
p<0.0001). RAC+IDX+WAY produced significantly fewer avoidance responses than
SAL+SAL+SAL (p<0.001), SAL+SAL+WAY (p<0.001), and SAL+IDX+WAY
(p<0.001). RAC+SAL+WAY produced significantly fewer avoidance responses than
SAL+SAL+SAL (p<0.001), SAL+SAL+WAY (p<0.001), and SAL+IDX+WAY
(p<0.001).
Escape responses differed significantly overall (F(5, 35) = 19.46, p<0.0001).
RAC+IDX+WAY produced significantly more escape responses than
SAL+SAL+SAL (p<0.001), SAL+SAL+WAY (p<0.001), and SAL+IDX+WAY
(p<0.001). RAC+SAL+WAY produced significantly more escape responses than
SAL+SAL+SAL (p<0.001), SAL+SAL+WAY (p<0.001), and SAL+IDX+WAY
(p<0.001). Escape failures did not differ significantly across treatments (χ2(5) =
10.63, p<0.0593). Intertrial crosses differed significantly overall (F(5, 35) = 4.769,
p<0.01) with RAC+IDX+WAY producing significantly fewer intertrial crosses than
SAL+SAL+SAL (p<0.01).
Raclopride + Idazoxan + Guanfacine
The data for avoidance responding for RAC+IDX+Guanfacine (RAC = 0.025
mg/kg, IDX = 1.5 mg/kg, Guanfacine (GF) = 0.08 mg/kg) are shown in figure 13.
Data for percent escape, escape failures and intertrial crosses for RAC+IDX+GF are

81

shown in table 14. Avoidance responses differed significantly overall (F(5, 35) =
4.735, p<0.01). RAC+IDX+GF produced higher percent avoidance than
RAC+IDX+SAL (p<0.05). Escape responses differed significantly overall (F(5, 35)
= 4.591, p<0.01). RAC+IDX+SAL produced significantly more escape responses
than SAL+SAL+SAL (p<0.05), SAL+IDX+GF (p<0.05), and GF alone (p<0.05).
Escape failures did not differ significantly across treatments (χ2(5) = 5.000, p =
0.4159). Intertrial crosses differed significantly overall (F(5, 35) = 4.994, p<0.01),
with SAL+IDX+GF differing significantly from GF alone (p<0.05), RAC+SAL+GF
(p<0.01) and RAC+IDX+SAL (p<0.05).
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Figure 11. Mean percent avoidance (+/- SEM) for raclopride (0.025 mg/kg) +
idazoxan (1.5 mg/kg) + WAY100635 (0.05 mg/kg) (RAC+IDX+WAY0.05) and
vehicle controls (SAL = saline). RAC+IDX and RAC+IDX+WAY0.05 had
significantly lower percent avoidance than SAL+SAL+SAL (***p<0.001).
RAC+SAL+WAY0.05 had significantly lower percent avoidance than
SAL+SAL+SAL (*p<0.05).
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Figure 11. Mean percent avoidance responding (+/- SEM) for raclopride + idazoxan +
WAY100635 (0.05 mg/kg).
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Table 12. Mean percent escape for raclopride (0.025 mg/kg) + idazoxan (1.5 mg/kg)
+ WAY100635 (0.05 mg/kg) (RAC+SAL+WAY) and vehicle controls (SAL
=saline).
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Treatment

%Escape

Escape

Intertrial

Failures

Crosses

SAL+SAL+SAL

1.4

0

12.4

SAL+SAL+WAY 0.05 mg/kg

0.7

0

12

SAL+IDX+WAY 0.05 mg/kg

2.1

0

6.6

RAC+SAL+WAY 0.05 mg/kg 36.1

1

1.9

RAC+IDX

56

2

2.6

RAC+IDX+WAY 0.05 mg/kg

68

3

1.9

Table 12. Mean percent escape, number of escape failures and intertrial crosses for
raclopride + idazoxan + WAY100635 (0.05 mg/kg).
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Figure 13. Mean percent avoidance (+/- SEM) for raclopride (0.025 mg/kg) +
idazoxan (1.5 mg/kg) + WAY100635 (0.2 mg/kg) (RAC+IDX+WAY0.2) and vehicle
controls (SAL =saline). RAC+SAL+WAY0.2, RAC+IDX, and RAC+IDX+WAY0.2
had significantly lower percent avoidance than SAL+SAL+SAL (***p<0.001).
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Figure 13. Mean percent avoidance responding (+/- SEM) for raclopride + idazoxan +
WAY100635 (0.2 mg/kg).
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Table 13. Mean percent escape, number of escape failures and mean number of
intertrial crosses for raclopride (0.025 mg/kg) + idazoxan (1.5 mg/kg) + WAY100635
(0.2 mg/kg) (RAC+IDX+WAY) and vehicle controls (SAL = saline).
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Treatment

%Escape

Escape

Intertrial

Failures

Crosses

SAL+SAL+SAL

1.4

0

12.4

SAL+SAL+WAY 0.2 mg/kg

0

0

6.4

SAL+IDX+WAY 0.2 mg/kg

1.4

0

9.9

RAC+SAL+WAY 0.2 mg/kg

58.1

3

0.3

RAC+IDX

56

2

2.6

RAC+IDX+WAY 0.2 mg/kg

45.7

3

0.5

Table 13. Mean percent escape, number of escape failures and intertrial crosses for
raclopride + idazoxan + WAY100635 (0.2 mg/kg).
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Figure 13. Mean percent avoidance (+/- SEM) for raclopride (0.025 mg/kg) +
idazoxan (1.5 mg/kg) + guanfacine (0.8 mg/kg) (RAC+IDX+GF) and vehicle controls
(SAL = saline). RAC+IDX+SAL had significantly lower percent avoidance than
SAL+SAL+SAL (*p<0.05) and RAC+IDX+GF (+p<0.05).
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Figure 13. Mean percent avoidance responding (+/- SEM) for raclopride + idazoxan +
guanfacine.
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Table 14. Mean percent escape, number of escape failures and mean number of
intertrial crosses for raclopride (0.025 mg/kg) + idazoxan (1.5 mg/kg) + guanfacine
(0.8 mg/kg) (RAC+IDX+GF) and vehicle controls (SAL = saline).

93

Treatment

%Escape

Escape

Intertrial

Failures

Crosses

SAL+SAL+SAL

0

0

9.6

GF

2.3

0

5

RAC+SAL+GF

30.5

1

3.6

RAC+IDX+SAL

41.2

2

4.9

SAL+IDX+GF

0

0

14.1

RAC+IDX+GF

6.1

1

10.4

Table 14. Mean percent escape, number of escape failures and intertrial crosses for
raclopride + idazoxan + guanfacine.
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Discussion
The current study was conducted to elucidate the role of 5-HT1A receptor
stimulation in the ability of idazoxan to reduce avoidance responding when paired
with an ineffective dose of a typical antipsychotic drug in the conditioned avoidance
response task. This was accomplished through the use of compounds selective for
dopamine D2 receptors, 5-HT1A receptors and α2 adrenoceptors. The α2 adrenoceptor
antagonists, idazoxan and yohimbine, significantly reduced avoidance responding
when paired with a low-dose of raclopride. Avoidance responding was also
significantly reduced by the combination of low-dose raclopride with the 5-HT1A
agonist, 8-OH-DPAT. Deficits in avoidance responding produced by the combination
of idazoxan and low-dose raclopride were not restored by the 5-HT1A antagonist,
WAY100635. The α2 adrenoceptor antagonist guanfacine, however, was able to
restore the avoidance responding deficits induced by the combination of raclopride
and idazoxan.
Dopamine D2 receptor antagonism is a critical mechanism for producing
antipsychotic effects and reliably reduces avoidance in the conditioned avoidance
response task. The present study used the typical antipsychotics, raclopride and
haloperidol. Both drugs were found to effectively reduce avoidance in the
conditioned avoidance response task, which is in agreement with previous studies
(Arnt, 1982; Hertel et al., 1999; Taboada et al., 1979; Wadenberg, 2000).
Alpha2 adrenoceptor antagonists have been previously shown to be ineffective
in producing antipsychotic effects in the conditioned avoidance response task. The α2
adrenoceptor antagonists used in these studies, idazoxan and yohimbine, were both
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ineffective in reducing avoidance responding, even at very high doses. These
findings are in agreement with previous research (Hertel et al., 1999; Wadenberg et
al., 2007). Serotonin1A receptor blockade is also known to be ineffective alone at
reducing avoidance responding. The current research demonstrated that the 5-HT1A
receptor antagonist, WAY100635, does not produce antipsychotic effects. These
findings are in agreement with previous research (Wadenberg et al., 2001).
Previous studies by Hertel and colleagues (1999) were successfully replicated,
which showed that an ineffective dose of the dopamine D2 receptor antagonist,
raclopride, when paired with the α2 adrenoceptor antagonist, idazoxan, produces an
antipsychotic effect in the conditioned avoidance response task. This finding was
replicated by another α2 adrenoceptor antagonist, yohimbine in the present study.
However, the present study failed to replicate research by Wadenberg and colleagues
(2007) which showed that the typical antipsychotic drug, haloperidol, reduced
avoidance responding when paired with idazoxan. The effects of idazoxan, when
paired with raclopride, were blocked by the α2 adrenoceptor agonist, guanfacine.
Because guanfacine, but not WAY, was able to restore avoidance responding, 5-HT1A
receptor stimulation may not be responsible for the ability of idazoxan and raclopride
to reduce avoidance responding when combined.
The reductions in avoidance responding produced by the combination of
raclopride and 8-OH-DPAT in the current study are in support of other research that
shows 5-HT1A stimulation contributes to antipsychotic effects. Prinssen and
colleagues (1999, 2002) reversed typical antipsychotic-induced catalepsy with 8-OHDPAT treatment, while preserving pre-clinical measures of therapeutic efficacy.
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Increases in prefrontal cortical dopamine are thought to attenuate the cognitive
deficits noted in schizophrenia, while striatal dopamine increases are thought to
contribute to the development of negative side effects such as movement disorders.
Microdialysis studies by Rollema and colleagues (2000) show that 8-OH-DPAT
increases antipsychotic drug-induced dopamine release in the prefrontal cortex
preferentially over striatal dopamine levels. Stimulation of 5-HT1A receptors by 8OH-DPAT also reduces antipsychotic-induced increases of dopamine in the nucleus
accumbens (Ichikawa & Meltzer, 2000). Therefore, the therapeutic effects of
antipsychotic drugs appear to be enhanced by 5-HT1A receptor stimulation, and the
negative symptoms and cognitive deficits of schizophrenia may be reduced by the
same mechanism.
The inability of WAY100635 (WAY) to restore avoidance responding deficits
induced by idazoxan and raclopride may indicate that 5-HT1A receptor stimulation
does not mediate the effects of idazoxan in the conditioned avoidance response task.
In addition to being ineffective at restoring avoidance deficits, WAY also caused
more escape failures and decreased intertrial crosses when given with the combined
treatment of raclopride and idazoxan. These data suggest that 5-HT1A receptor
blockade may potentiate the cataleptic effects of antipsychotic drugs. Evidence from
previous behavioral and in vivo research has shown the effects of 5-HT1A receptor
stimulation and blockade on typical and atypical antipsychotic drug efficacy.
Raclopride- and haloperidol-induced catalepsy is enhanced by co-treatment with
WAY (Prinssen et al., 2000; Prinssen et al., 2002). WAY does not, however,
interrupt the anti-cataleptic effects of idazoxan (Kleven et al., 2005). WAY alone
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increases dopamine levels in motor regions of the brain, whereas 8-OH-DPAT does
not, indicating that 5-HT1A receptor blockade may increase motor side effects such as
EPS (Ichikawa & Meltzer, 2000).
It is important to note that α2 adrenoceptor blockade, while sufficient to
contribute to antipsychotic effects, may not be necessary. The atypical antipsychotic
drugs amisulpiride and aripiprazole have therapeutic efficacy with a low propensity
for EPS, but do act as antagonists at α2 adrenoceptors (Natesan et al., 2008; DeLeon
et al., 2004). Because glutamate receptors are found to be abnormal in patients with
schizophrenia, and glutamate antagonists induce hallucinations in healthy subjects,
glutamate NMDA receptor agonists have been implicated in the treatment of
schizophrenia. Specifically, these drugs reduce the occurrence of negative symptoms,
and are effective in improving cognitive functioning in patients with schizophrenia
(see Goff & Coyle, 2001, for review). The current study therefore supports the
hypothesis that the combination of α2/D2 receptor blockade produces antipsychotic
effects.
Although the present research supports the hypothesis that combined α 2/D2
receptor blockade produces an antipsychotic effect in the conditioned avoidance
response task, it is unclear whether this combination constitutes an atypical
antipsychotic drug. As a preclinical tool, the conditioned avoidance response task can
only be used to identify antipsychotic effects, and does not differentiate between
typical and atypical antipsychotic drugs, as both have the ability to reduce avoidance
responding. Antipsychotic atypicality has previously been defined as an
antipsychotic with therapeutic efficacy and a low propensity for EPS. In animal
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models, this definition of atypicality requires that a drug does not induce catalepsy at
doses correlated with those that are effective in preclinical antipsychotic animal
models. The conditioned avoidance response task is best used for demonstrating
positive symptom efficacy, which may not necessarily include 5-HT1A receptor
stimulation. Future research could utilize another behavioral measure, such as the
paw test, drug discrimination or prepulse inhibition, to clarify the type of
antipsychotic effects produced by the combined blockade of α2 adrenoceptors and
dopamine D2 receptors. Given the anti-cataleptic effects of α2 adrenoceptor
antagonists such as idazoxan and yohimbine, it may be that the α 2/D2 hypothesis of
antipsychotic atypicality is accurate.
Previous research in this lab and others has sought to evaluate the role of 5HT1A receptor stimulation in idazoxan’s effects on atypicality. Kleven and colleagues
(2005) found that idazoxan reverses typical antipsychotic-induced catalepsy using a
crossed-leg position bar test. While pretreatment with WAY100635 blocked the
effect of idazoxan to attenuate haloperidol-induced catalepsy using the crossedlegged position test, WAY100635 failed to do so for the bar test. These results
suggest that 5-HT1A receptor agonism may only play a modest role in mediating the
anti-cataleptic effects of idazoxan. Drug discrimination studies in this laboratory
have found that partial generalization to idazoxan occurs with 8-OH-DPAT treatment,
while WAY100635 partially blocks the idazoxan cue (Zornio, Kopp, Winiarski,
Jacobson, Rehberg, et al., 2008). These data support previous findings that idazoxan
acts as an agonist at 5-HT1A receptors. Drug discrimination does not, however,
identify antipsychotic efficacy. Microdialysis studies in this laboratory have
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demonstrated that idazoxan potentiates raclopride-induced increases in prefrontal
cortical dopamine. This effect was significantly attenuated by pre-treatment with
WAY100635 (Prus, Jacobson, Keusch, Li, Huang et
al., 2007). These data suggest that 5-HT1A receptor stimulation may
contribute to drug effects that are not detected in the conditioned avoidance response
task.
In conclusion, the inability of WAY100635 to restore avoidance responding
deficits induced by the combination of raclopride and idazoxan may reflect the limits
of the conditioned avoidance response task in identifying atypical antipsychotic
drugs. It is possible that 5-HT1A receptor stimulation, although possibly favorable for
improving cognitive deficits and negative symptoms, may not mediate improvements
in positive symptoms as measured by the conditioned avoidance response task. The
ability of guanfacine to restore deficits in avoidance responding induced by the
combined treatment of raclopride and idazoxan indicates that α2 adrenoceptor
blockade may mediate the positive symptom efficacy of an antipsychotic drug
treatment. Therefore, hypotheses regarding the atypicality of combined α 2/D2
receptor stimulation should be explored using a range of pre-clinical evaluations that
not only predict efficacy for positive symptoms, but also negative symptoms and
cognitive deficits as well.
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APPENDIX A

Conditioned avoidance training program (MedPC)

\Conditioned Avoidance Response
\Written by Adam Prus and Sarah Jacobson on December 23, 2008
\15 min session
\---------SHUTTLE BOX-----------\
FAN
\
\ X
X
\ X
DOOR
X
\ LEFTKEY
D
RIGHTKEY
\ LEFTNOISE
D
RIGHTNOISE
\ X
D
X
\ X
D
X
\ X-R1---------------------R2-X
\
LEFTSHOCK
RIGHTSHOCK
\
SHOCK
\----------------------------------------------------------------------------------------------------\Display: 1. Time
2. TrialStart
3. Trial
4. Avoidance
5. Escape
\
6. B4Trial_Crosses 7. Intertrial cross
8. Blank
9. %Avoidance
10. %Escape
\
11.Shock On/Off
12. Blank
13.Blank
14. Av_Avoid_Lat 15. Avg_Escape_Latency
\----------------------------------------------------------------------------------------------------^Leftkey = 1
^Rightkey = 2
^Shock = 6
^Door = 5
^Leftnoise = 3
^Rightnoise = 4
^Leftshock = 7
^Rightshock = 8
^Fan = 10
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\A=left entries
\B=right entries
\C=Variables
\D=number of trials
\J=Avoidance latency counter
\K=Escape latency counter
LIST X = 20",25",30",35",40"
DIM C = 30 \within session variables for program functionality
DIM E = 45 \avoidance per trial
DIM F = 45 \escape per trial
DIM G = 45 \time to escape per trial (escape latency)
DIM H = 45 \trial where animal failed to escape
DIM I = 45 \number of intertrial crosses based on trial number.
Counts are made after trial is complete.
DIM L = 45 \time to avoid per trial (avoidance latency)
DIM M = 9 \for organizing total session dependent variables
\C(1)=Time till next session counter
\C(2)=Equal to 1 when between trials
\C(3)=Sum of avoidance latencies
\C(4)=Sum of escape latencies
\C(5)=Time till escape
\C(6)=Left warning stimuli
\C(7)=Right warning stimuli
\C(8)=R2 Beam Counter
\C(9)=R2 Beam long enough
\C(10)=R7 Beam Counter
\C(11)=R7 Beam Counter long
\C(12)=Between shock indicator
\C(13)=#R4 or R5 tripped - not a full escape response
\C(14)=
\C(15)=
\
\M(1)=Avoidance counter
\M(2)=Percent avoidance
\M(3)=Avoidance Latency
\M(4)=Escape counter
\M(5)=Percent escape
\M(6)=Escape Latency
\
\Z1=Failure to escape counter
\Z2=Successful escape
\Z3=Before trial crossings
\Z4=Run State Sets for intertrial crosses
\Z5=Intertrial crossings counter
\Z6=Avoidance
\Z7=Escape
\Z8=
\Z9=
\Z10=Countdown to next trial
\Z11=Reset after beam in opposing side broken during avoidance
\Z12=Before trial 1 crossings counter
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\Z13=Indicates when the last trial is finished. Prevents the
session from ending during the trial.
\Z14=Start avoidance latency counter
\Z15=Stop avoidance latency counter
\Z16=Trial started
\Z17=Start avoidance timer
\Z18=Failure to emit avoidance response
\Z19=Stop avoidance timer (avoidance response emitted)
\Z20=Start intershock interval timer
\Z21=
\Z22=Failure to escape during intershock interval
S.S.1,
S1,
#Start: ON ^Leftkey,^Rightkey,^Shock,^Door,^Fan;Set D=999; Set
C(2)=1;Set M(1)=999;Set M(4)=999;Z3--->S2
S2,
30":Set D=1;Show 3,Trial,D;Z16--->S6
S3,
0.1": RANDI Y = X;Z4;Set C(2)=1;Set C(1)=Y;Set C(9)=0;Set
C(11)=0;Set C(13)=0;Z10;Z13--->S4
S4,
Y#T:Z13;Z16;Set C(2)=0--->S5
S5,
1":ADD D;Show 3,Trial,D--->S6
S6,\Where's the rat?
#R1:ON ^Leftnoise, ^Rightnoise;Add C(6);Z14;Z17--->S7 \left
warning stimulus on
#R2:ON ^Leftnoise, ^Rightnoise;Add C(7);Z14;Z17--->S10 \right
warning stimulus on
S7, \Left side for failure to avoid or avoidance response
10":ON ^Leftshock, ^Rightshock;Z1;Z15;Show 11,SHOCK,1--->S8
\failure to avoid WHY NOT 10"?
#R2: OFF ^Leftnoise, ^Rightnoise;Z6;Z13;Z15--->S3 \avoidance
S8,
0.5": OFF ^Leftshock, ^Rightshock;Z20;Show 11,OFF,1--->S9
S9, \Shock after 2.5" for left side
2.5":ON ^Leftshock, ^Rightshock;Set C(13)=0;Z22;Show
11,SHOCK,1--->S8
#R2:Z2;Z13;Z22;OFF ^LEFTNOISE, ^RIGHTNOISE--->S3 \escape
S10, \Right side
10":ON ^Leftshock, ^rightshock;Z1;Z15;Show 11,SHOCK,1--->S11
\failure to avoid
#R1:OFF ^Leftnoise, ^Rightnoise;Z6;Z13;Z15--->S3 \avoidance
response
S11, \Right side
0.5": OFF ^Leftshock, ^Rightshock;Z20;Show 11,OFF,1--->S12
S12, \Right side
2.5":ON ^Leftshock, ^Rightshock;Set C(13)=0;Z22;Show
11,SHOCK,1--->S11
#R1:Z2;Z13;Z22;OFF ^LEFTNOISE, ^RIGHTNOISE--->S3 \escape
response
\--------------------------------------------------------------
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S.S.2, \Failure to escape timer
S1,
#Z1:--->S2
S2,
50":OFF ^Leftnoise, ^Rightnoise, ^LeftKey, ^Rightkey,
^Shock;Set H(D)=1--->Stopabortflush
#Z2: IF M(4)=999 [@True, @False]
@True:Set M(4)=0;Add M(4);Set F(D)=1;Set
M(5)=(M(4)/D)*100;Show 4,Avoidance,M(1);Show
9,%_Avoidance,M(2);Show 5,Escape,M(4);Show 10,%_Escape,M(5)--->S1
@False:Add M(4);Set F(D)=1;Set M(5)=(M(4)/D)*100;Show
4,Avoidance,M(1);Show 9,%_Avoidance,M(2);Show 5,Escape,M(4);Show
10,%_Escape,M(5)--->S1
\-------------------------------------------------------------S.S.3, \Time to escape (escape latency)
S1,
#Z1:Set K=0--->S2
S2,
0.1": Set K=K+0.1--->S2
#Z2:Set G(D)=K;Set C(4)=C(4)+K;Z13--->S1
\-------------------------------------------------S.S.4, \Intertrial crosses for left to right
S1,
#Z4:--->S2
S2,
#R1:IF C(2)=0 [@True,@False]
@True:--->S1
@False:--->S3
#Z16:--->S1
S3,
#R2:IF C(2)=0 [@True,@False]
@True:--->S1
@False:Z5--->S1
#Z16:--->S1
S.S.5, \Intertrial crosses for right to left
S1,
#Z4:--->S2
S2,
#R2:IF C(2)=0 [@True,@False]
@True:--->S1
@False:--->S3
#Z16:--->S1
S3,
#R1:IF C(2)=0 [@True,@False]
@True:--->S1
@False:Z5--->S1
#Z16:--->S1
S.S.6, \Intertrial counts
S1,
#Z5:Add M(8);Add I(D);Show 7,IT_Crosses,M(8)--->SX
\-------------------------------------------------S.S.7, \Avoidance counter
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S1,
#Z6: IF M(1)=999 [@True, @False]
@True:Set M(1)=0; Add M(1);Set E(D)=1;Set
M(2)=(M(1)/D)*100;Show 4,Avoidance,M(1);Show
9,%_Avoidance,M(2);Show 5,Escape,M(4);Show 10,%_Escape,M(5)--->S1
@False: Add M(1);Set E(D)=1;Set M(2)=(M(1)/D)*100;Show
4,Avoidance,M(1);Show 9,%_Avoidance,M(2);Show 5,Escape,M(4);Show
10,%_Escape,M(5)--->S1
\-------------------------------------------------S.S.8, \Session timer
S1,
#Start:Set T = 900--->S2
S2,
1":Set T=T-1;Set M(2)=(M(1)/D)*100;Set M(5)=(M(4)/D)*100;Show
1,Seconds,T;Show 4,Avoidance,M(1);Show 9,%_Avoidance,M(2);Show
5,Escape,M(4);Show 10,%_Escape,M(5);IF T=0 [@True,@False] \
@True:IF C(2)=0 [@True, @False]
@True:--->S3
@False:OFF ^LeftKey, ^Rightkey, ^Shock;Set
M(3)=C(3)/M(1);Set M(6)= C(4)/M(4);Show
14,Avoid_Latency,M(3);Show 15,Escape_Latency,M(6)-->Stopabortflush
@False:--->S2
S3,
#Z13:OFF ^LeftKey, ^Rightkey, ^Shock;Set M(3)=C(3)/M(1);Set
M(6)=C(4)/M(4);Show 14,Avoid_Latency,M(3);Show
15,Escape_Latency,M(6)--->Stopabortflush
\------------------------------------------------------------S.S.9, \Before trial crosses for left to right
S1,
#Z3:--->S2
S2,
#R1:IF C(2)=0 [@True,@False]
@True:--->S1
@False:--->S3
#Z16:--->S1
S3,
#R2:IF C(2)=0 [@True,@False]
@True:--->S1
@False:Z12--->S1
#Z16:--->S1
S.S.10, \Before trial crosses for right to left
S1,
#Z3:--->S2
S2,
#R2:IF C(2)=0 [@True,@False]
@True:--->S1
@False:--->S3
#Z16:--->S1
S3,
#R1:IF C(2)=0 [@True,@False]
@True:--->S1
@False:Z12--->S1
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#Z16:--->S1
S.S.11, \Before trial counts
S1,
#Z12:Add M(7);Show 6,Before_Crosses,M(7)--->S1
\---------------------------------------------------------------S.S.12, \Time to avoidance (avoidance latency)
S1,
#Z14:Set J=0--->S2
S2,
0.1": Set J=J+0.1--->S2
#Z15:Set L(D)=J; IF J>=10 [@True, @False]
@True:--->S1
@False:Set C(3)=C(3)+J--->S1
\---------------------------------------------------------------S.S.13, \Time until next trial
S1,
#Z10:--->S2
S2,
1":Set C(1)=C(1)-100;Show 2,Next_Trial,C(1);IF C(1)=0
[@True,@False]
@True:--->S1
@False:--->S2
\------------------------------------------------------------------S.S.14, \Resets the indicator that the rat failed to exit the
compartment completely during an avoidance response
S1,
#Z11:--->S2
S2,
0.02": Set C(13)=0--->S1
\-------------------------------------------------------------------S.S.15, \10" Avoidance timer
S1,
#Z17:--->S2
S2,
10":Z18--->S3
#Z19:--->S1
S3,
0.01":Z18--->S3
#Z19:--->S1
\-------------------------------------------------------------------S.S.16, \2.5" Intershock interval timer
S1,
#Z20:--->S2
S2,
2.5":Z21--->S3
#Z22:--->S1
S3,
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0.01":Z21--->S3
#Z22:--->S1
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APPENDIX B

Conditioned avoidance testing program (MedPC)

\Conditioned Avoidance Response
\10 min test session
\Written by Adam Prus and Sarah Jacobson on December 23, 2008
\10 min session
\---------SHUTTLE BOX-----------\
FAN
\
\ X
X
\ X
DOOR
X
\ LEFTKEY
D
RIGHTKEY
\ LEFTNOISE
D
RIGHTNOISE
\ X
D
X
\ X
D
X
\ X-R1---------------------R2-X
\
LEFTSHOCK
RIGHTSHOCK
\
SHOCK
\----------------------------------------------------------------------------------------------------\Display: 1. Time
2. TrialStart
3. Trial
4. Avoidance
5. Escape
\
6. B4Trial_Crosses 7. Intertrial cross
8. Blank
9. %Avoidance
10. %Escape
\
11.Shock On/Off
12. Blank
13.Blank
14. Av_Avoid_Lat 15. Avg_Escape_Latency
\----------------------------------------------------------------------------------------------------^Leftkey = 1
^Rightkey = 2
^Shock = 6
^Door = 5
^Leftnoise = 3
^Rightnoise = 4
^Leftshock = 7
^Rightshock = 8
^Fan = 10
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\A=left entries
\B=right entries
\C=Variables
\D=number of trials
\J=Avoidance latency counter
\K=Escape latency counter
LIST X = 20",25",30",35",40"
DIM C = 30 \within session variables for program functionality
DIM E = 45 \avoidance per trial
DIM F = 45 \escape per trial
DIM G = 45 \time to escape per trial (escape latency)
DIM H = 45 \trial where animal failed to escape
DIM I = 45 \number of intertrial crosses based on trial number.
Counts are made after trial is complete.
DIM L = 45 \time to avoid per trial (avoidance latency)
DIM M = 9 \for organizing total session dependent variables
\C(1)=Time till next session counter
\C(2)=Equal to 1 when between trials
\C(3)=Sum of avoidance latencies
\C(4)=Sum of escape latencies
\C(5)=Time till escape
\C(6)=Left warning stimuli
\C(7)=Right warning stimuli
\C(8)=R2 Beam Counter
\C(9)=R2 Beam long enough
\C(10)=R7 Beam Counter
\C(11)=R7 Beam Counter long
\C(12)=Between shock indicator
\C(13)=#R4 or R5 tripped - not a full escape response
\C(14)=
\C(15)=
\
\M(1)=Avoidance counter
\M(2)=Percent avoidance
\M(3)=Avoidance Latency
\M(4)=Escape counter
\M(5)=Percent escape
\M(6)=Escape Latency
\
\Z1=Failure to escape counter
\Z2=Successful escape
\Z3=Before trial crossings
\Z4=Run State Sets for intertrial crosses
\Z5=Intertrial crossings counter
\Z6=Avoidance
\Z7=Escape
\Z8=
\Z9=
\Z10=Countdown to next trial
\Z11=Reset after beam in opposing side broken during avoidance
\Z12=Before trial 1 crossings counter
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\Z13=Indicates when the last trial is finished. Prevents the
session from ending during the trial.
\Z14=Start avoidance latency counter
\Z15=Stop avoidance latency counter
\Z16=Trial started
\Z17=Start avoidance timer
\Z18=Failure to emit avoidance response
\Z19=Stop avoidance timer (avoidance response emitted)
\Z20=Start intershock interval timer
\Z21=
\Z22=Failure to escape during intershock interval
S.S.1,
S1,
#Start: ON ^Leftkey,^Rightkey,^Shock,^Door,^Fan;Set D=999; Set
C(2)=1;Set M(1)=999;Set M(4)=999;Z3--->S2
S2,
30":Set D=1;Show 3,Trial,D;Z16--->S6
S3,
0.1": RANDI Y = X;Z4;Set C(2)=1;Set C(1)=Y;Set C(9)=0;Set
C(11)=0;Set C(13)=0;Z10;Z13--->S4
S4,
Y#T:Z13;Z16;Set C(2)=0--->S5
S5,
1":ADD D;Show 3,Trial,D--->S6
S6,\Where's the rat?
#R1:ON ^Leftnoise, ^Rightnoise;Add C(6);Z14;Z17--->S7 \left
warning stimulus on
#R2:ON ^Leftnoise, ^Rightnoise;Add C(7);Z14;Z17--->S10 \right
warning stimulus on
S7, \Left side for failure to avoid or avoidance response
10":ON ^Leftshock, ^Rightshock;Z1;Z15;Show 11,SHOCK,1--->S8
\failure to avoid WHY NOT 10"?
#R2: OFF ^Leftnoise, ^Rightnoise;Z6;Z13;Z15--->S3 \avoidance
S8,
0.5": OFF ^Leftshock, ^Rightshock;Z20;Show 11,OFF,1--->S9
S9, \Shock after 2.5" for left side
2.5":ON ^Leftshock, ^Rightshock;Set C(13)=0;Z22;Show
11,SHOCK,1--->S8
#R2:Z2;Z13;Z22;OFF ^LEFTNOISE, ^RIGHTNOISE--->S3 \escape
S10, \Right side
10":ON ^Leftshock, ^rightshock;Z1;Z15;Show 11,SHOCK,1--->S11
\failure to avoid
#R1:OFF ^Leftnoise, ^Rightnoise;Z6;Z13;Z15--->S3 \avoidance
response
S11, \Right side
0.5": OFF ^Leftshock, ^Rightshock;Z20;Show 11,OFF,1--->S12
S12, \Right side
2.5":ON ^Leftshock, ^Rightshock;Set C(13)=0;Z22;Show
11,SHOCK,1--->S11
#R1:Z2;Z13;Z22;OFF ^LEFTNOISE, ^RIGHTNOISE--->S3 \escape
response
\--------------------------------------------------------------
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S.S.2, \Failure to escape timer
S1,
#Z1:--->S2
S2,
50":OFF ^Leftnoise, ^Rightnoise, ^LeftKey, ^Rightkey,
^Shock;Set H(D)=1--->Stopabortflush
#Z2: IF M(4)=999 [@True, @False]
@True:Set M(4)=0;Add M(4);Set F(D)=1;Set
M(5)=(M(4)/D)*100;Show 4,Avoidance,M(1);Show
9,%_Avoidance,M(2);Show 5,Escape,M(4);Show 10,%_Escape,M(5)--->S1
@False:Add M(4);Set F(D)=1;Set M(5)=(M(4)/D)*100;Show
4,Avoidance,M(1);Show 9,%_Avoidance,M(2);Show 5,Escape,M(4);Show
10,%_Escape,M(5)--->S1
\-------------------------------------------------------------S.S.3, \Time to escape (escape latency)
S1,
#Z1:Set K=0--->S2
S2,
0.1": Set K=K+0.1--->S2
#Z2:Set G(D)=K;Set C(4)=C(4)+K;Z13--->S1
\-------------------------------------------------S.S.4, \Intertrial crosses for left to right
S1,
#Z4:--->S2
S2,
#R1:IF C(2)=0 [@True,@False]
@True:--->S1
@False:--->S3
#Z16:--->S1
S3,
#R2:IF C(2)=0 [@True,@False]
@True:--->S1
@False:Z5--->S1
#Z16:--->S1
S.S.5, \Intertrial crosses for right to left
S1,
#Z4:--->S2
S2,
#R2:IF C(2)=0 [@True,@False]
@True:--->S1
@False:--->S3
#Z16:--->S1
S3,
#R1:IF C(2)=0 [@True,@False]
@True:--->S1
@False:Z5--->S1
#Z16:--->S1
S.S.6, \Intertrial counts
S1,
#Z5:Add M(8);Add I(D);Show 7,IT_Crosses,M(8)--->SX
\-------------------------------------------------S.S.7, \Avoidance counter
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S1,
#Z6: IF M(1)=999 [@True, @False]
@True:Set M(1)=0; Add M(1);Set E(D)=1;Set
M(2)=(M(1)/D)*100;Show 4,Avoidance,M(1);Show
9,%_Avoidance,M(2);Show 5,Escape,M(4);Show 10,%_Escape,M(5)--->S1
@False: Add M(1);Set E(D)=1;Set M(2)=(M(1)/D)*100;Show
4,Avoidance,M(1);Show 9,%_Avoidance,M(2);Show 5,Escape,M(4);Show
10,%_Escape,M(5)--->S1
\-------------------------------------------------S.S.8, \Session timer
S1,
#Start:Set T = 600--->S2
S2,
1":Set T=T-1;Set M(2)=(M(1)/D)*100;Set M(5)=(M(4)/D)*100;Show
1,Seconds,T;Show 4,Avoidance,M(1);Show 9,%_Avoidance,M(2);Show
5,Escape,M(4);Show 10,%_Escape,M(5);IF T=0 [@True,@False] \
@True:IF C(2)=0 [@True, @False]
@True:--->S3
@False:OFF ^LeftKey, ^Rightkey, ^Shock;Set
M(3)=C(3)/M(1);Set M(6)= C(4)/M(4);Show
14,Avoid_Latency,M(3);Show 15,Escape_Latency,M(6)-->Stopabortflush
@False:--->S2
S3,
#Z13:OFF ^LeftKey, ^Rightkey, ^Shock;Set M(3)=C(3)/M(1);Set
M(6)=C(4)/M(4);Show 14,Avoid_Latency,M(3);Show
15,Escape_Latency,M(6)--->Stopabortflush
\------------------------------------------------------------S.S.9, \Before trial crosses for left to right
S1,
#Z3:--->S2
S2,
#R1:IF C(2)=0 [@True,@False]
@True:--->S1
@False:--->S3
#Z16:--->S1
S3,
#R2:IF C(2)=0 [@True,@False]
@True:--->S1
@False:Z12--->S1
#Z16:--->S1
S.S.10, \Before trial crosses for right to left
S1,
#Z3:--->S2
S2,
#R2:IF C(2)=0 [@True,@False]
@True:--->S1
@False:--->S3
#Z16:--->S1
S3,
#R1:IF C(2)=0 [@True,@False]
@True:--->S1
@False:Z12--->S1
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#Z16:--->S1
S.S.11, \Before trial counts
S1,
#Z12:Add M(7);Show 6,Before_Crosses,M(7)--->S1
\---------------------------------------------------------------S.S.12, \Time to avoidance (avoidance latency)
S1,
#Z14:Set J=0--->S2
S2,
0.1": Set J=J+0.1--->S2
#Z15:Set L(D)=J; IF J>=10 [@True, @False]
@True:--->S1
@False:Set C(3)=C(3)+J--->S1
\---------------------------------------------------------------S.S.13, \Time until next trial
S1,
#Z10:--->S2
S2,
1":Set C(1)=C(1)-100;Show 2,Next_Trial,C(1);IF C(1)=0
[@True,@False]
@True:--->S1
@False:--->S2
\------------------------------------------------------------------S.S.14, \Resets the indicator that the rat failed to exit the
compartment completely during an avoidance response
S1,
#Z11:--->S2
S2,
0.02": Set C(13)=0--->S1
\-------------------------------------------------------------------S.S.15, \10" Avoidance timer
S1,
#Z17:--->S2
S2,
10":Z18--->S3
#Z19:--->S1
S3,
0.01":Z18--->S3
#Z19:--->S1
\-------------------------------------------------------------------S.S.16, \2.5" Intershock interval timer
S1,
#Z20:--->S2
S2,
2.5":Z21--->S3
#Z22:--->S1
S3,
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0.01":Z21--->S3
#Z22:--->S1
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